WO2003035065A1 - Benzimidazoles et analogues et leur utilisation comme inhibiteurs de proteines kinases - Google Patents

Benzimidazoles et analogues et leur utilisation comme inhibiteurs de proteines kinases Download PDF

Info

Publication number
WO2003035065A1
WO2003035065A1 PCT/GB2002/004763 GB0204763W WO03035065A1 WO 2003035065 A1 WO2003035065 A1 WO 2003035065A1 GB 0204763 W GB0204763 W GB 0204763W WO 03035065 A1 WO03035065 A1 WO 03035065A1
Authority
WO
WIPO (PCT)
Prior art keywords
benzoimidazol
pyrazol
carboxylic acid
dimethyl
amide
Prior art date
Application number
PCT/GB2002/004763
Other languages
English (en)
Inventor
Michael Louis Edwards
Paul Joseph Cox
Shelley Amendola
Stephanie Daniele Deprets
Timothy Alan Gillespy
Christopher David Edlin
Andrew David Morley
Charles J. Gardner
Brian Pedgrift
Hervé Bouchard
Didier Babin
Laurence Gauzy
Alain Le Brun
Tahir Nedeem Majid
John C. Reader
Lloyd J. Payne
Nawaz M. Khan
Michael Cherry
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0113868A external-priority patent/FR2831537B1/fr
Priority claimed from GB0206895A external-priority patent/GB0206895D0/en
Priority claimed from GB0206893A external-priority patent/GB0206893D0/en
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Priority to AU2002334217A priority Critical patent/AU2002334217B2/en
Priority to MXPA04003954A priority patent/MXPA04003954A/es
Priority to JP2003537632A priority patent/JP5039268B2/ja
Priority to IL16157602A priority patent/IL161576A0/xx
Priority to CA2465247A priority patent/CA2465247C/fr
Priority to BR0213562-0A priority patent/BR0213562A/pt
Priority to EP02801954A priority patent/EP1441725A1/fr
Publication of WO2003035065A1 publication Critical patent/WO2003035065A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Definitions

  • This invention is directed to benzimidazoles of formula (Ix), their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of the protein kinases.
  • protein kinases belong especially to the following group: EGFR, Fak, FLK-1, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, flt-1, IGF-1R, KDR, PDGFR, tie2, VEGFR, ITK and SYK.
  • Protein kinases are a family of enzymes that participate in the signalling events which control the activation, growth and differentiation of cells in response to extracellular mediators and to changes in ' the environment. In general, these kinases fall into several groups; those which preferentially catalyse the phosphorylation of hydroxy groups of serine and/or threonine residues and those which preferentially catalyse the phosphorylation of hydroxy groups of tyrosine residues [S.K.Hanks and T.Hunter, FASEB. J., 1995, 9, pages 576-596]. Such phosphorylations may greatly modify the function of the proteins; thus, protein kinases play an important role in regulating a wide variety of cell processes including, especially, metabolism, cell proliferation, cell differentiation or cell survival.
  • Angiogenesis or the formation of new blood vessels by sprouting from the preexisting vasculature is of central importance for embryonic development and organogenesis. Should the need arise, the vascular system has the potential to generate a network of new vessels so as to maintain the correct functioning of the tissues and organs.
  • Angiogenesis is a complex multistage process which includes activation, migration, proliferation and survival of endothelial cells. In adults, angiogenesis is fairly limited, appearing mainly only in the processes of repair after an injury or of vascularization of the endometrium. (Merenmies et al., Cell Growth & Differentiation, 8, 3-10, 1997).
  • VEGF-R2 vascular endothelial growth factor receptor 2, also known as KDR, kinase insert domain receptor, or FLK-1
  • FGF-R fibroblast growth factor receptor
  • Tie-2 vascular endothelial growth factor receptor 2
  • VEGFRs Vascular Endothelial Growth Factor receptors
  • the family VEGFR includes VEGFR-1 (Flt-1), VEGFR-2 (KDR) and VEGFR3 (Flt4).
  • the receptor VEGF-R2 which is expressed only in the endothelial cells, binds to the angiogenic growth factor VEGF, and thus serves as a transduction signal mediator via the activation of its intracellular kinase domain.
  • VEGF-R2 direct inhibition of the kinase activity of VEGF-R2 makes it possible to reduce the phenomenon of angiogenesis in the presence of exogenous VEGF (Strawn et al., Cancer Research, 56, 3540-3545, 1996), this process being demonstrated especially with the aid of VEGF-R2 mutants (Millauer et al., Cancer Research, 56, 1615-1620, 1996).
  • the VEGF-R2 receptor appears to have no other function in adults than that associated with the angiogenic activity of VEGF.
  • a selective inhibitor of the kinase activity of VEGF-R2 should show only little toxicity.
  • KDR inhibitors thus especially constitute anti-angiogenic agents and such agents might be used as a first line treatment against the emergence or regrowth of malignant tumours.
  • the inhibition or regulation of VEGFR-2 (KDR) thus provides a powerful new mechanism of action for the treatment of a large number of solid tumours.
  • the present patent application thus relates particularly to novel inhibitors of the VEGFR-2 (KDR) receptor that may be used especially for anti-angiogenic treatment in oncology.
  • KDR VEGFR-2
  • the protein kinases which preferentially catalyse the phosphorylation of hydroxy groups of serine and/or threonine residues include for example, protein kinase C isoforms [A.C.Newton, J. Biol. Chem., 1995, 270, pages 28495-28498] and a group of cyclin-dependent kinases such as cdk2 [J.Pines, Trends in Biochemical Sciences, 1995, 18, pages 195-197].
  • the protein kinases which preferentially catalyse the phosphorylation of hydroxy groups of serine and/or threonine residues include membrane-spanning growth factor receptors such as the epidermal growth factor receptor [S.Iwashita and M.Kobayashi, Cellular Signalling, 1992, 4, pages 123-132], and cytosolic non-receptor kinases such as p561ck, p59fYn, ZAP-70 and csk kinases [C.Chan et. al., Ann. Rev. Immunol, 1994, 12, pages 555-592].
  • membrane-spanning growth factor receptors such as the epidermal growth factor receptor [S.Iwashita and M.Kobayashi, Cellular Signalling, 1992, 4, pages 123-132]
  • cytosolic non-receptor kinases such as p561ck, p59fYn, ZAP-70 and csk kinases [C.Chan et. al
  • SYK Single Tyrosine Kinase
  • Fc ⁇ Rl the high affinity IgE receptor
  • Fc ⁇ Rl the high affinity IgE receptor
  • T and B lymphocytes The signal transduction pathways present in mast, T and B cells have common features.
  • the ligand binding domain of the receptor lacks intrinsic tyrosine kinase activity.
  • ITAMs immunoreceptor tyrosine based activation motifs
  • TCR T cell receptor
  • BCR B cell receptor
  • SYK belongs to a unique class of tyrosine kinases that have two tandem Src homology 2 (SH2) domains and a C terminal catalytic domain. These SH2 domains bind with high affinity to ITAMs and this SH2 -mediated association of SYK with an activated receptor stimulates SYK kinase activity and localises SYK to the plasma membrane.
  • SH2 domains bind with high affinity to ITAMs and this SH2 -mediated association of SYK with an activated receptor stimulates SYK kinase activity and localises SYK to the plasma membrane.
  • SYK is further involved in the activation of platelets stimulated via the low-affinity IgG receptor (Fc gamma-RIIA) or stimulated by collagen [F.Yanaga et al., Biochem. J., 1995, 311, (PL 2) pages 471- 478].
  • Fc gamma-RIIA low-affinity IgG receptor
  • ITK is a T cell specific tyrosine kinase of the Tec family that is required for normal Th2 function. Asthma is a disease characterised by increased Th2 cytokine production including IL-4. An inhibitor of ITK should therefore have an impact on disease progression in asthma through inhibition of Th2 cytokine production.
  • the present invention is directed to pharmaceutical compositions comprising compounds of general formula (Ix):-
  • X represents C-R ⁇ and W, Y and Z, which may be identical or different, represent CH or CR ⁇ ; or
  • W represents CH, X represents N, Y represents CH or CR ⁇ , and Z represents CH or CR ⁇ ; or
  • W represents N
  • X represents CH or CR ⁇
  • Y represents CH and CR ⁇
  • Z represents CH or CR ⁇
  • W represents N
  • X represents CH or CR ⁇
  • Y represents N
  • Z is CH or CR ⁇
  • W represents N
  • X represents CH or CR ⁇
  • Y represents CH or CR ⁇
  • Z represents N
  • W represents N
  • X represents N
  • Y represents CH or CR ⁇
  • Z represents CH or CR ⁇
  • A5 represents H or alkyl
  • R 2 and R 3 are such that:
  • R 5 is alkyl, alkenyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;
  • the invention concerns the compounds of formula (Ix) as defined above wherein R 1
  • R ' is hydrogen or alkyl
  • Patient includes both human and other mammals.
  • Acid bioisostere means a group which has chemical and physical similarities producing broadly similar biological properties to a carboxy group (see Lipinski, Annual Reports in Medicinal Chemistry, 1986,2 l,p283 "Bioisosterism In Drug Design”; Yun, Hwahak Sekye, 1993, 33, pages 576-579 "Application Of Bioisosterism To New Drug Design”; Zhao, Huaxue Tongbao, 1995, pages 34-38 "Bioisosteric Replacement And Development Of Lead Compounds In Drug Design”; Graham, Theochem, 1995, 343, pages 105-109 "Theoretical Studies Applied To Drug Desig ab initio Electronic Distributions In Bioisosteres”).
  • Alkenyl means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain and containing one or more double bonds. Preferred alkenyl groups have 2 to about 12 carbon atoms in the chain; and more preferably 2 to about 6 carbon atoms (e.g. 2 to 4 carbon atoms) in the chain.
  • Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear chain; here a linear alkenyl chain.
  • “Lower alkenyl” means about 2 to about 4 carbon atoms in the chain, which may be straight or branched.
  • alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexylbutenyl, decenyl, and 3,7-dimethyl-octa-2,6-dienyl.
  • Alkoxy means an alkyl-O- group in which the alkyl group is as described herein.
  • exemplary alkoxy groups include difluoromethoxy, methoxy, trifluoromethoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, pentoxy, hexoxy and heptoxy, and also the linear or branched positional isomers thereof.
  • Alkoxycarbonyl means an alkyl-O-CO- group in which the alkyl group is as described herein.
  • exemplary alkoxycarbonyl groups include methoxy- and ethoxycarbonyl.
  • Alkyl means, unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched chain having about 1 to about 15 carbon atoms in the chain, optionally substituted by one or more halogen atoms. Particular alkyl groups have from 1 to about 6 carbon atoms.
  • “Lower alkyl” as a group or part of a lower alkoxy, lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl group means unless otherwise specified, an aliphatic hydrocarbon group which may be a straight or branched chain having 1 to about 4 carbon atoms in the chain.
  • Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl, 3-pentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl and dodecyl, and also the linear or branched positional isomers thereof.
  • Exemplary alkyl groups substituted by one or more halogen atoms include trifluoromethyl, difluoromethyl, trifluoroethyl and difluoroethyl.
  • Alkylene means an aliphatic bivalent radical derived from a straight or branched alkyl group, in which the alkyl group is as described herein.
  • Exemplary alkylene radicals include methylene, ethylene and trimethylene.
  • Alkylenedioxy means an -O-alkylene-O- group in which alkylene is as defined above.
  • exemplary alkylenedioxy groups include methylenedioxy and ethylenedioxy.
  • Alkylsulfmyl means an alkyl-SO- group in which the alkyl group is as previously described.
  • Preferred alkylsulfmyl groups are those in which the alkyl group is C
  • Alkylsulfonyl means an alkyl-S0 2 - group in which the alkyl group is as previously described.
  • Preferred alkylsulfonyl groups are those in which the alkyl group is Ci ⁇ alkyl.
  • Preferred alkylsulfonylcarbamoyl groups are those in which the alkyl group is C ⁇ alkyl.
  • Alkylthio means an alkyl-S- group in which the alkyl group is as previously described.
  • exemplary alkylthio groups include methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, isopentylthio, hexylthio, isohexylthio and heptylthio, and also the linear or branched positional isomers thereof.
  • Preferred alkylthio groups have not more than 4 carbon atoms.
  • Alkynyl means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which group may be a straight or branched chain having about 2 to about 15 carbon atoms in the chain.
  • Preferred alkynyl groups have 2 to about 12 carbon atoms in the chain; and more preferably 2 to about 6 carbon atoms (e.g. 2 to 4 carbon atoms) in the chain.
  • Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, i-butynyl, 3-methylbut-2-ynyl, and n-pentynyl.
  • Aroyl means an aryl-CO- group in which the aryl group is as described herein.
  • Exemplary aroyl groups include benzoyl and 1- and 2-naphthoyl.
  • Aroylamino is an aroyl-NH- group wherein aroyl is as previously defined.
  • Aryl as a group or part of a group denotes: (i) an optionally substituted monocyclic or multicyclic aromatic carbocyclic moiety of about 6 to about 14 carbon atoms, such as phenyl or naphthyl; or (ii) an optionally substituted partially saturated multicyclic aromatic carbocyclic moiety in which a monocyclic aromatic carbocyclic moiety and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure, such as a tetrahydronaphthyl, indenyl or indanyl ring.
  • aryl groups may be substituted with one or more aryl group substituents, which may be the same or different, where "aryl group substituent" includes, for example, acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulfmyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfmyl, arylsulfonyl, arylthio, carboxy (or an acid bioisostere), cyano, cycloalkyl, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, heterocycloalkyl, hydroxy, nitro, trifluoromethyl
  • Arylalkyl means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contain a Ci _4alkyl moiety. Exemplary arylalkyl groups include benzyl, 2-phenethyl and naphthlenemethyl.
  • Arylalkyloxy means an arylalkyl-O- group in which the arylalkyl group is as previously described.
  • exemplary arylalkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy.
  • Arylalkyloxycarbonyl means an arylalkyl-O-CO- group in which the arylalkyl group is as previously described.
  • An exemplary arylalkyloxycarbonyl group is benzyloxycarbonyl.
  • Arylalkylthio means an arylalkyl-S- group in which the arylalkyl group is as previously described.
  • An exemplary arylalkylthio group is benzylthio.
  • Aryloxy means an aryl-O- group in which the aryl group is as previously described.
  • exemplary aryloxy groups include phenoxy and naphthoxy, each optionally substituted.
  • exemplary aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.
  • Arylsulfmyl means an aryl-SO- group in which the aryl group is as previously described.
  • Arylsulfonyl means an aryl-S0 2 - group in which the aryl group is as previously described.
  • Arylthio means an aryl-S- group in which the aryl group is as previously described.
  • exemplary arylthio groups include phenylthio and naphthylthio.
  • Carbocyclic means a saturated ring system comprising carbon atoms.
  • cyclic amines include pyrrolidine, piperidine, morpholine, piperazine, indoline, pyrindoline, tetrahydroquinoline and the like groups.
  • Cycloalkenyl means a non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having about 3 to about 10 carbon atoms.
  • Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl and cycloheptenyl.
  • Cycloalkyl means a saturated monocyclic or bicyclic ring system of about 3 to about 10 carbon atoms, optionally substituted by oxo.
  • Exemplary monocyclic cycloalkyl rings include C3_gcycloalkyl rings such as cyclopropyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • Cycloalkylalkyl means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described.
  • Exemplary monocyclic cycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.
  • Halo or "halogen” means fluoro, chloro, bromo, or iodo. Preferred are fluoro, bromo and chloro.
  • Haloallcyl means an alkyl group having about 1 to about 6 carbon atoms in the chain and substituted by one or more halo atoms.
  • exemplary haloalkyl groups include trifluoromethyl.
  • exemplary heteroaryl groups include pyridylcarbonyl.
  • Heteroaroylamino means a heteroaroyl-NH- group in which the heteroaryl moiety is as previously described.
  • Heteroaryl as a group or part of a group denotes: (i) an optionally substituted aromatic monocyclic or multicyclic organic moiety of about 5 to about 10 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulfur (examples of such groups include benzoimidazolyl, benzothiazolyl, furyl, imidazolyl, indazolyl, indolyl, indolizinyl, isoxazolyl, isoquinolinyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl groups, optionally substituted by one or more aryl group
  • Optional substituents include one or more "aryl group substituents" as defined above, except where otherwise defined.
  • R 1 is heteroaryl this may particularly represent pyrazolyl, triazolyl, isoxazolyl, isothiazolyl, thiazolyl, oxazolyl, imidazolyl, pyrrolyl, furanyl, thiophenyl, phenyl, pyridinyl, oxodihydropyridinyl, pyrimidinyl, indolyl, indazolyl, thienopyrazolyl, tetrahydroindazolyl, tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl, oxodihydropyridazinyl, tetrahydropyrrolopyrazolyl, oxotetrahydropyrrolopyrazolyl, tetrahydropyranopyrazolyl, te
  • Heteroarylalkyl means a heteroaryl-alkyl- group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a C ⁇ alkyl moiety. Exemplary heteroarylalkyl groups include pyridylmethyl.
  • Heteroarylalkyloxy means an heteroarylalkyl-O- group in which the heteroarylalkyl group is as previously described.
  • exemplary heteroaryloxy groups include optionally substituted pyridylmethoxy.
  • Heteroaryloxy means an heteroaryl-O- group in which the heteroaryl group is as previously described.
  • exemplary heteroaryloxy groups include optionally substituted pyridyloxy.
  • Heterocycloalkyl means: (i) a cycloalkyl group of about 3 to 10 ring members which contains one or more heteroatoms or heteroatom-containing groups selected from O, S and NY" and may be optionally substituted by oxo (examples of such groups include hexahydropyran, pyrrolidinyl, piperidinyl, tetrahydropyranyl and octahydro-pyrido[l,2-c]pyrimidin-l-one); (ii) a partially saturated multicyclic heterocarbocyclic moiety in which an aryl (or heteroaryl) ring, each optionally substituted by one or more "aryl group substituents," and a heterocycloalkyl group are fused together to form a cyclic structure (examples of such groups include chromanyl, dihydrobenzofuranyl, indolinyl and pyrindolinyl groups).
  • Heterocycloalkylalkyl means a heterocycloalkyl-alkyl- group in which the heterocycloalkyl and alkyl moieties are as previously described.
  • Hydroalkyl means an alkyl group substituted by one or hydroxy groups.
  • NH(alk) and “N(alk)(alk)” denote an amino radical substituted, respectively, with one or two alkyl radicals, such alkyl radicals being linear or branched and chosen from alkyl radicals as defined above, preferably containing not more than 4 carbon atoms.
  • Prodrug means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of formula (Ix), including N-oxides thereof.
  • an ester of a compound of formula (Ix) containing a hydroxy group may be convertible by hydrolysis in vivo to the parent molecule.
  • an ester of a compound of formula (Ix) containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule.
  • Suitable esters of compounds of formula (Ix) containing a hydroxy group are, for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis- ⁇ -hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates and quinates.
  • Suitable esters of compounds of formula (Ix) containing a carboxy group are, for example, those described by FJ.Leinweber, Drug Metab. Res., 1987, 18, page 379.
  • esters of compounds of formula (Ix) containing a hydroxy group may be formed from acid moieties selected from those described by Bundgaard et. al., J. Med. Chem., 1989, 32 , pages 2503-2507, and include substituted (aminomethyl)-benzoates, for example dialkylamino-methylbenzoates in which the two alkyl groups may be joined together and/or interrupted by an oxygen atom or by an optionally substituted nitrogen atom, e.g. an allcylated nitrogen atom, more especially (morpholino-methyl)benzoates, e.g. 3- or 4-(morpholinomethyl)-benzoates, and (4-alkylpiperazin-l-yl)benzoates, e.g. 3- or 4-(4-alkylpiperazin-l-yl)benzoates.
  • substituted (aminomethyl)-benzoates for example dialkylamino-methylbenzoates in which the two alkyl groups may be joined together and/or
  • base addition salts may be formed and are simply a more convenient form for use; in practice, use of the salt form inherently amounts to use of the free acid form.
  • the bases which can be used to prepare the base addition salts include preferably those which produce, when combined with the free acid, pharmaceutically acceptable salts, that is, salts whose cations are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the cations.
  • Pharmaceutically acceptable salts including those derived from alkali and alkaline earth metal salts, within the scope of the invention include those derived from the following bases: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, tetramethylammonium hydroxide, and the like.
  • acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the anions.
  • compositions are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures.
  • Pharmaceutically acceptable salts within the scope of the invention include those derived from mineral acids and organic acids, and include hydrohalides, e.g.
  • salts of compounds of the invention of compounds of formula (Ix) are useful for the purposes of purification of the compounds, for example by exploitation of the solubility differences between the salts and the parent compounds, side products and/or starting materials by techniques well known to those skilled in the art.
  • compounds of the present invention of formula (Ix) may contain asymmetric centres. These asymmetric centres may independently be in either the R or S configuration. It will be apparent to those skilled in the art that certain compounds of the invention may also exhibit geometrical isomerism. It is to be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds of formula (Ix) hereinabove. Such isomers can be separated from their mixtures, by the application or adaptation of known methods, for example chromatographic techniques and recrystallisation techniques, or they are separately prepared from the appropriate isomers of their intermediates. Additionally, tautomers of the compounds of formula (Ix) are possible, and the present invention is intended to include all tautomeric forms of the compounds.
  • One subject of the present invention is thus the compounds of formula (I):
  • X represents C-R 2 and W, Y and Z, which may be identical or different, represent CH or CR 3 ;
  • R 1 represents aryl or heteroaryl chosen from pyrazolyl, triazolyl, imidazolyl, indolyl, indazolyl, thieno- pyrazolyl, tetrahydroindazolyl, tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl, oxodihydropyridazinyl, tetrahydropyrrolopyrazolyl, oxotetrahydropyrrolopyrazolyl, tetrahydropyranopyrazolyl, tetrahydropyridinopyrazolyl, and oxodihydropyridinopyrazolyl radicals, all these radicals being optionally substituted with one or more radicals X 1 , X 2 or X 3 chosen from H, halogen, hal
  • R 2 and R 3 together form a 5- to 6-membered carbon-based ring containing one or more hetero atoms, which may be identical or different, chosen from O, N and S,
  • R 5 represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl.
  • Y 1 and Y 2 are such that: either Y 1 and Y 2 , which may be identical or different, represent H and optionally substituted alkyl, alkenyl, cycloalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl, or Y 1 and Y 2 form, together with the nitrogen atom to which they are attached, a cyclic amino radical,
  • Y 3 and Y 4 are such that: either Y 3 and Y 4 , which may be identical or different, represent hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl or Y 3 and Y 4 form, together with the nitrogen atom to which they are attached, an optionally substituted cyclic amino radical,
  • a 5 represents H or alkyl
  • radicals containing allcyl, aryl and heteroaryl being themselves optionally substituted with one or more radicals chosen from halogen atoms and alkyl radicals, free, salified or esterified carboxyl radicals and acylamino radicals NH-C(0)R 5 ,
  • the phenyl radicals furthermore being optionally substituted with a dioxole radical
  • n an integer from 0 to 2
  • W necessarily represents H or unsubstituted alkyl
  • Xa represents C-R 2 a and Wa, Ya and Za, which may be identical or different, represent CH or CR 3 a;
  • R 5 a represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl, all these radicals being optionally substituted
  • Y [ a and Y 2 a are such that: either Y'a and Y 2 a, which may be identical or different, represent H, alkyl, alkoxyalkyl, aryloxyalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkyl, aryl and heteroaryl, all these radicals being optionally substituted, or Y'a and Y 2 a form, together with the nitrogen atom to which they are attached, an optionally substituted cyclic amino radical, Y 3 a and Y 4 a are such that: either Y 3 a and Y 4 a, which may be identical
  • Y 3 a and Y 4 a form, together with the nitrogen atom to which they are attached, a cyclic amino radical
  • a 5 represents H or alkyl
  • radicals containing allcyl, aryl and heteroaryl themselves being optionally substituted with one or more radicals chosen from halogen atoms and alkyl radicals, alkoxy radicals, free, salif ⁇ ed or esterified carboxyl radicals and acylamino radicals NH-C(0)R 6 a,
  • the phenyl radicals furthermore being optionally substituted with a dioxole radical
  • R 6 a is chosen from the values of R 5 a,
  • n an integer from 0 to 2
  • X represents C-R 2 and W, Y and Z, which may be identical or different, represent CH or CR 3 ;
  • R 1 represents aryl or heteroaryl chosen from pyrazolyl, triazolyl, imidazolyl, indolyl, indazolyl, thieno- pyrazolyl, tetrahydroindazolyl, tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl, oxodihydropyridazinyl, tetrahydropyrrolopyrazolyl, oxotetrahydropyrrolopyrazolyl, tetrahydropyranopyrazolyl, tetrahydropyridinopyrazolyl, and oxodihydro-pyridinopyrazolyl radicals, all these radicals optionally being substituted with one or more radicals X 1 , X 2 or X 3 chosen from H, halogen,
  • R 6 represents H and C1-C4 alkyl
  • n represents an integer from 0 to 2
  • W necessarily represents H or unsubstituted alkyl, the said compounds of formula (F) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral bases.
  • R 1 can comprise one, two or three substituents represented by X 1 , X 2 and X 3 .
  • Xa represents C-R 2 a and Wa, Ya and Za, which may be identical or different, represent CH or CR 3 a;
  • R 4 a represents alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, heteroarylalkyl or arylalkyl, all these radicals being optionally substituted with one or more radicals chosen from aryl, OH, OR 5 a,
  • R5a represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl,
  • R 6 a represents H and C1-C4 alkyl, n represents an integer from 0 to 2,
  • Y 3 a and Y 4 a form, together with the nitrogen atom to which they are attached, a cyclic amino radical
  • Y 3 a and Y 4 a are such that: either Y 3 a and Y 4 a, which may be identical or different, represent hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl, or Y 3 a and Y 4 a form, together with the nitrogen atom to which they are attached, a cyclic amino radical,
  • a 5 represents H or alkyl, the said compounds of formula (la) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral bases.
  • A represents a saturated heterocyclic radical which is either a 5- or 6-membered monocyclic radical or a bicyclic radical that is not more than 10-membered, these members being such that at least two of them represent a nitrogen atom and the others, which may be identical or different, represent a carbon member or a hetero atom member chosen from O, N and S, this heterocycle A being optionally substituted with one or more radicals XA 1 , XA 2 or XA 3 chosen from the values indicated hereinabove for the radicals X 1 , X 2 or X 3 ,
  • Ai, A 2 , A 3 and A 4 which may be identical or different, are chosen from a hydrogen atom, halogen atoms and hydroxyl, alkyl, alkenyl, alkoxy, nitro, cyano, aryl, heteroaryl and aryloxy radicals, a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA 6 A 7 such that either A 6 and A 7 , which may be identical or different, are chosen from a hydrogen atom and optionally substituted alkyl, alkoxyalkyl, phenoxyalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyl radicals, or A 6 and A 7 form, together with the nitrogen atom to which they are attached, an optionally substituted 5- or 6-membered cyclic radical, it being understood that two consecutive radicals among Ai, A 2 ,
  • R 6 b represents hydrogen, alkyl, alkenyl, cycloalkyl, phenyl, phenylalkyl and cycloalkylalkyl,
  • n an integer from 0 to 2
  • Aa represents a pyrazolyl, triazolyl or indazolyl radical, this heterocycle Aa being optionally substituted with one or more radicals XA 1 , XA 2 or XA 3 chosen from the values indicated hereinabove for the radicals X 1 , X 2 or X 3 ,
  • Aia, A 2 a, A 3 a and A 4 a which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkoxy, nitro, cyano, phenyl and phenoxy radicals, and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA aA 7 a such that either A ⁇ a and A 7 a, which may be identical or different, are chosen from a hydrogen atom and alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, thienylalkyl and pyridylalkyl radicals, or A6a and A7a form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, morph
  • a 5 a represents a hydrogen atom or an alkyl radical
  • the phenyl and phenoxy radicals above being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, free, salified or esterified carboxyl, and dioxole radicals, all the alkyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than 6 carbon atoms,
  • the said compounds of formula (IAa) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAa).
  • R 4 a, Y'a, Y 2 a and R 6 b having the values defined above and alk representing a linear or branched alkyl radical including not more than 6 carbon atoms and optionally substituted as indicated above.
  • alkylthio radicals are such that the sulfur atom is optionally oxidized to sulfone or sulfoxide with one or two oxygen atoms.
  • Tables I, II and III described below give examples of compounds illustrating the present invention, with in particular substituents chosen from the values of X 1 , X 2 and X 3 as defined above.
  • X represents hydrogen, alkynyl or NHCOCH 2 Ph which is optionally substituted.
  • the subject of the present invention is thus the compounds of formula (I) as defined above in which the substituents of the said compounds of formula (I) have the any of the values indicated as defined hereinabove and in which the aryl radicals represent the phenyl and naphthyl radicals; the heteroaryl radicals represent the furyl, thienyl, benzothienyl, thianthrenyl, pyridyl, pyrazolyl, benzimidazolyl, benzofuran, isobenzofuran and dihydrobenzofuran radicals; the cycloalkyl radicals represent a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl radical; the heterocycloalkyl radicals represent the hexahydropyran, piperidyl or morpholino radicals; the heterocycloalkylalkyl radicals represent the hexahydropyranylalkyl, piperidylalkyl and
  • One subject of the present invention is, more particularly, the compounds of formula (I) as defined above corresponding to the formula (IA):
  • A represents a saturated heterocyclic radical which is either a 5- or 6-membered monocyclic radical or a bicyclic radical that is not more than 10-membered, these members being such that at least two of them represent a nitrogen atom and the others, which may be identical or different, represent a carbon member or a hetero atom member chosen from O, N and S, this heterocycle A optionally being substituted with one or more radicals XA 1 , XA 2 or XA 3 chosen from halogen atoms, alkyl, alkoxy or alkylthio radicals or thienyl radicals optionally substituted with an allcyl radical,
  • Ai, A 2 , A 3 and A which may be identical or different, are chosen from a hydrogen atom, halogen atoms and hydroxyl, alkyl, alkoxy, nitro, cyano, phenyl and phenoxy radicals, a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA 6 A 7 such that either A 6 and A 7 , which may be identical or different, are chosen from a hydrogen atom and alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl and heteroarylalkyl radicals, or A 6 and A 7 form, together with the nitrogen atom to which they are attached, a 5- or 6-membered cyclic radical, it being understood that two consecutive radicals among A A 2 , A 3 and A can form, with the benzimidazole radical to which they are attached, a 5- to 6-membered carbon-based ring containing one or more
  • a subject of the present invention is also, more particularly, the compounds of formula (I) as defined above, corresponding to the formula (IAb):
  • Ab represents a pyrazolyl or indazolyl radical optionally substituted with one or two radicals chosen from halogen atoms and OH, alkyl, alkynyl, -OR ⁇ b (including alkoxy), -COR 6 b, -0-COR 6 b, -OS(0) n R 6 b, -0(CH 2 ) n -CO-R 6 b, phenyl, phenylalkyl, CF 3 , OCF 3 , N0 2 , CN, NYWb,
  • Y'b and Y 2 b which may be identical or different, are chosen from hydrogen and optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, phenyl, naphthyl, phenoxy, phenylalkyl, phenylalkylthio and naphthylalkyl or Y'b and Y 2 b form, together with the nitrogen atom to which they are attached, a piperidyl, hexahydrofuran, morpholinyl or morpholinylalkyl radical,
  • Aib, A 2 b, A 3 b and A t b which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkenyl, -OR 6 b (including alkoxy), -CO-R 6 b, -0-COR 6 b, -OS(0) n R 6 b, -0(CH 2 ) n -CO-R 6 b, nitro, cyano, furyl, thienyl, benzothienyl, naphthyl, thianthrenyl, phenyl and phenoxy radicals and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA 6 bA 7 b such that either A 6 b and A 7 b, which may be identical or different, are chosen from hydrogen and alkyl, alkoxyalkyl, phenoxyalkyl, phenyl, phenylalkyl
  • a 5 b represents a hydrogen atom
  • n an integer from 0 to 2
  • R 6 b representing hydrogen, alkyl, alkenyl, cycloalkyl, phenyl, pyridyl, thienyl, naphthyl, isoxazole, adamentyl, quinoline, quinolone, dihydroquinolone, -NH-phenyl, phenylalkyl and cycloalkylalkyl, all these radicals being optionally substituted with a morpholino, piperidyl or phenyl radical itself optionally substituted with one or more radicals chosen from halogen atoms and the cyano, CF 3 , OCF 3 , alkyl, phenyl-S(0)n-alk-phenyl, alkoxy, NH 2 , NHalk, N(alk) 2 , S0 2 NH 2 , S0 2 Nalk or S0 2 N(alk) 2 radical,
  • the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).
  • Y'b and Y 2 b which may be identical or different, are chosen from hydrogen and optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, phenyl, naphthyl, phenoxy, phenylalkyl, phenylalkylthio and naphthylalkyl or Y L b and Y 2 b form, together with the nitrogen atom to which they are attached, a piperidyl, hexahydrofuran, morpholinyl or morpholinylalkyl radical,
  • Ajb, A 2 b, A 3 b and AJ which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkenyl, alkoxy, nitro, cyano, furyl, thienyl, benzothienyl, naphthyl, thianthrenyl, phenyl and phenoxy radicals and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA 6 bA 7 b such that either
  • a 6 b and A 7 b which may be identical or different, are chosen from hydrogen and alkyl, alkoxyalkyl, phenoxyalkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, naphthylalkyl, thienylalkyl, piperidylalkyl, pyridylalkyl, benzothienylalkyl, pyrazolylalkyl, dihydrobenzofuranylalkyl, hexahydropyranylalkyl, ethylenedioxyphenylalkyl and benzimidazolylalkyl radicals, all these radicals being optionally substituted, or A 6 b and A 7 b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical, the piperazinyl radical being optionally substituted on the second nitrogen atom
  • a 5 b represents a hydrogen atom
  • Y ! b and Y 2 b which may be identical or different, are chosen from hydrogen and optionally substituted alkyl, cycloalkyl, cycloalkylalkyl, phenyl, naphthyl, phenoxy, phenylalkyl, phenylalkylthio and naphthylalkyl or Y'b and Y 2 b form, together with the nitrogen atom to which they are attached, a piperidyl, hexahydrofuran, morpholinyl or morpholinylalkyl radical,
  • Aib, A 2 b, A 3 b and A 4 b which may be identical or different, are such that two of them represent hydrogen and the other two, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkenyl, -OR 6 b (including alkoxy), -CO-R 6 b, -0-COR 6 b, -OS(0) n R 6 b, -0(CH 2 ) n -CO-R ⁇ b, nitro, cyano, furyl, thienyl, benzothienyl, naphthyl, thianthrenyl, phenyl and phenoxy radicals and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA ⁇ bA 7 b such that either A ⁇ b and
  • a 7 b which may be identical or different, are chosen from hydrogen and allcyl, alkoxyalkyl, phenoxyalkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, naphthylalkyl, thienylalkyl, piperidylalkyl, pyridylalkyl, benzothienylalkyl, pyrazolylalkyl, dihydrobenzofuranylalkyl, hexahydropyranylalkyl, ethylenedioxyphenylalkyl and benz- imidazolylalkyl radicals, all these radicals being optionally substituted, or A 6 b and A 7 b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical, the piperazinyl radical being optionally substituted on the second nitrogen atom with an al
  • R ⁇ b representing hydrogen, alkyl, alkenyl, cycloalkyl, phenyl, pyridyl, thienyl, naphthyl, isoxazole, adamentyl, quinoline, quinolone, dihydroquinolone, -NH-phenyl, phenylalkyl and cycloalkylalkyl, all these radicals being optionally substituted with a morpholino, piperidyl or phenyl radical itself optionally substituted with one or more radicals chosen from halogen atoms and the cyano, CF 3 , OCF 3 , alkyl, phenyl-S(0)n-alk-phenyl, alkoxy, NH 2 , NHalk, N(alk) 2 , S0 2 NH 2 , S0 2 Nalk or S0 2 N(alk) 2 radical,
  • the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).
  • a subject of the present invention is thus in particular the compounds of formula (I) as defined above corresponding to the formula (IAb) in which Ab represents a pyrazolyl or indazolyl radical optionally substituted with one or more radicals chosen from halogen atoms and alkyl, alkoxy and thienyl radicals,
  • Aib, A 2 b, A 3 b and AJa which may be identical or different, are chosen from a hydrogen atom; halogen atoms; radicals of the following types: hydroxyl, alkyl, alkenyl optionally substituted with phenyl itself optionally substituted with one or more halogen atoms, alkoxy, nitro, cyano, furyl, thienyl optionally substituted with acyl COalk, benzothienyl, naphthyl, thianthrenyl, phenyl and phenoxy which are optionally substituted; and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA 6 bA 7 b such that either A 6 b and A 7 b, which may be identical or different, are chosen from hydrogen and radicals of the following types : alkyl, alkoxyalkyl containing not more than 6 carbon atoms, phenoxyalkyl optionally substituted with
  • a 6 b and A 7 b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical, the piperazinyl radical being optionally substituted on the second nitrogen atom with an alkyl radical, it being understood that two consecutive radicals among A[b, A 2 b, A 3 b and A 4 b can form, with the benzimidazole radical to which they are attached, an optionally substituted
  • a 5 a represents a hydrogen atom
  • the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).
  • a subject of the present invention is thus in particular the compounds of formula (I) as defined above corresponding to the formula (IAb) in which Ab, A]b, A 2 b, A 3 b, A 4 b and A 5 b have any of the meanings indicated hereinabove,
  • NA ⁇ bA 7 b either one of A 6 b and A 7 b represents a hydrogen atom or an alkyl radical and the other of A ⁇ b and A 7 b is chosen from the values defined for A ⁇ b and A 7 b, or A ⁇ b and A 7 b form, together with the nitrogen atom to which they are attached, a 5- or 6-membered cyclic radical,
  • the said compounds of formula (IAb) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IAb).
  • a subject of the present invention is thus in particular the compounds of formula (I) as defined above in which X, W, Y and Z are such that two or three of them represent CH and the others are chosen from the values of CR 2 or CR 3 and, if appropriate, i.e., when two of them represent CH and CR 2 and CR 3 are adjacent to each other, can form a dioxole radical,
  • the present invention thus relates in particular to the compounds of formula (IA) as defined above in which Ai, A 2 , A 3 and A 4 are such that two or three of them represent a hydrogen atom and the others are chosen from the values of Ai, A 2 , A 3 and A 4 and, if appropriate, i.e., when two of them represent a hydrogen atom and the other two are on adjacent carbons, can form a dioxole radical,
  • the said compounds of formula (IA) being in any possible racemic, enantiomeric or diastereoisomeric isomer form, and also the addition salts with mineral and organic acids or with mineral and organic bases of the said compounds of formula (IA).
  • a subject of the present invention is also, more particularly, the compounds of formula (I) as defined above, corresponding to the formula (IAa):
  • Aa represents a pyrazolyl, triazolyl or indazolyl radical, this heterocycle Aa being optionally substituted with one or more radicals XA 1 , XA 2 or XA 3 chosen from halogen atoms, alkyl, alkoxy or alkylthio radicals and thienyl radicals optionally substituted with an alkyl radical, Aia, A 2 a, A 3 a and A 4 a, which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl, alkoxy, nitro, cyano, phenyl and phenoxy radicals, and a carboxyl radical which is free, salified, esterified with an alkyl radical or amidated with a radical NA ⁇ aA 7 a such that either A 6 a and A 7 a, which may be identical or different, are chosen from a hydrogen atom and alkyl, phenyl, phenylalkyl
  • One subject of the present invention is, more particularly, the compounds of formula (I) as defined above in which R represents a pyrazolyl or indazolyl radical, the other substituents having the values indicated above or below.
  • Aia represents hydrogen or carboxyl or forms a ring with the adjacent member A 2 a
  • - t a represents hydrogen or carboxyl or forms a ring with the adjacent member A 3 a
  • a 2 a represents a carboxyl radical that is free, salified, esterified with an optionally substituted alkyl radical or an amidated carboxyl as indicated above or below,
  • a 5 represents hydrogen
  • Ab represents a pyrazolyl or indazolyl radical optionally substituted with one or more radicals chosen from halogen atoms and alkyl, alkoxy and thienyl radicals,
  • Aib, A 2 b, A 3 b and A b which may be identical or different, are chosen from a hydrogen atom, halogen atoms, hydroxyl, alkyl and alkoxy, nitro, cyano, phenyl and phenoxy radicals, and a carboxyl radical that is free, salified, esterified with an alkyl radical or amidated with a radical NA 6 bA 7 b such that either A ⁇ b and A 7 b, which may be identical or different, are chosen from alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl and furylalkyl radicals, or A 6 b and A 7 b form, together with the nitrogen atom to which they are attached, a pyrrolidinyl, morpholino or piperazinyl radical optionally substituted on the second nitrogen atom with an alkyl radical, it being understood that two consecutive radicals from among Ajb, A 2 b
  • a 5 b represents a hydrogen atom, the phenyl and phenoxy radicals above being optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino and free, salified or esterified carboxyl radicals, all the allcyl, alkoxy and alkylthio radicals above being linear or branched and containing not more than
  • R 1 may particularly represent optionally substituted heteroaryl.
  • exemplary optionally substituted heteroaryls include dihydrofuropyrazolyl, imidazolyl, indazolyl, indolyl, isoxazolyl, oxodihydropyridazinyl, oxodihydropyridinopyrazolyl, oxodihydropyridinyl, oxotetrahydropyrrolopyrazolyl, pyrazolyl, thiazolyl, thienopyrazolyl, tetrahydrocyclopentapyrazolyl, tetrahydroindazolyl, tetrahydropyranopyrazolyl, tetahydropyridinopyrazolyl, tetrahydropyrrolopyrazolyl or triazolyl.
  • heteroaryl moiety and R ' is hydrogen can exist in the tautomeric forms
  • W may particularly represent CH when X is CR 2 , Y is CH or CR ⁇ and Z are CH or CRA
  • W may also particularly represent CH when X is N, Y is CH or CR ⁇ and Z is CH or CR?.
  • W may also particularly represent N when X is CH or CR 2 , Y is CH or CR ⁇ and Z is CH or CR ⁇ .
  • W may also particularly represent N when X is CH or CR 2 , Y is CH or CR ⁇ and Z is N.
  • W, X, Y, Z and R ' are as hereinbefore defined for compounds of formula (Ix), and R° and R" are independently selected from hydrogen, carboxy, cyano, halo, haloalkyl, hydroxy, nitro, R 4 ,
  • R° represents: (i) hydrogen; (ii) C 1 . 4 alkyl [e.g. CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 or CH(CH 3 )CH 2 CH 3 ];
  • R ⁇ represents: (i) hydrogen; (ii) Ci.yalkyl [e.g. -CH3, -CH 2 CH 2 CH 3 , -CH(CH ) 2 or -CH 2 -CH?-CH(CH 3 ) 2 ];
  • aryl e.g. phenyl
  • R 4 is aryl [e.g.,
  • R 4 is heteroaryl [e.g.
  • a preferred group of compounds of the invention are compounds of formula (Ixa) in which:- W represents CH; X represents CH; Y represents CH; Z represents CH or C-CH3; R? represents hydrogen; R° > represents (i) hydrogen, (ii) C ⁇ alkyl [e.g. CH3, CH 2 CH_3, CH(CH3) 2 or
  • R 9 represents (i) hydrogen; (ii) C yalkyl [e.g. -CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 or -CH 2 -CH 2 -CH(CH 3 ) 2 ]; (iii) aryl [e.g.
  • R 4 is aryl [e.g.
  • a further preferred group of compounds of the invention are compounds of formula (Ixa) in which:- W represents CH; X represents CH; Z represents CH; Y represents (i) C-C j ⁇ alkyl [e.g. C-CH3,
  • C-Br C-Cl or C-F
  • C-haloalkyl e.g. C-CF3
  • C-heteroaryl e.g. C V N or
  • C-OR 4 e.g. C-OCH 3 , C-OCH 2 CFL , C-OCHF 2 , C-OCF 3
  • R° represents hydrogen
  • R° represents (i) hydrogen
  • R 9 represents (i) hydrogen; (ii) C ⁇ yalkyl [e.g. -CH3, -CH 2 CH 2 CH , -CH(CH 3 ) 2 or -CH 2 -CH 2 -CH(CH ) 2 ]; (iii) aryl [e.g. phenyl]; (iv) -C ⁇ NY ⁇ 2 [e.g.
  • R 4 is alkyl optionally substituted by aryl, cycloalkyl, heteroaryl, heterocycloalkyl, NY ⁇ 2 or -OR 5 [e.g.
  • R 4 is aryl [e.g.
  • a further preferred group of compounds of the invention are compounds of formula (Ixa) in which:- W represents CH; X represents C-CH3, C-CH 2 CH 3 , C-CH(CH 3 ) 2 , C-OCH3, C-OCH 2 CH 3 , C-Br or
  • Y represents C-CH3, C-CH 2 CH , C-OCH3, C-Br, C-Cl, C-F, C ⁇ or
  • R 7 represents hydrogen
  • R& represents (i) hydrogen, (ii) C ⁇ alkyl [e.g. CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 or CH(CH )CH 2 CH 3 ], (iii) -SR 4 [e.g.
  • R 4 is aryl [e.g,
  • R 4 is cycloalkyl [e.g. — NH-C(O) or ], (d) R 4 is
  • a further preferred group of compounds of the invention are compounds of formula (Ixa) in which: -W represents CH; X represents CH; Y represents C-CH3; Z represents C-CH3; R 7 represents hydrogen;
  • R s represents (i) hydrogen, (ii) Chalky! [e.g. CH3, CH 2 CH 3 , CH(CH 3 ) 2 or CH(CH 3 )CH 2 CH ], (iii)
  • -SR 4 [e.g. -S— CH, , -S— CH,CH, or — S— CH
  • R 4 is aryl [e.g.
  • a further preferred group of compounds of the invention are compounds of formula (Ixa) in which:-W represents CH; X represents CR 2 and Y represents CR ⁇ where R 2 and R ⁇ form the group -CH 2 -0-CH 2 -; Z represents CH; R? represents hydrogen; R° > represents (i) hydrogen, (ii) Ci _4alkyl [e.g. CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 or CH(CH 3 )CH 2 CH 3 ], (iii) -SR 4 [e.g. — S— CH 3 , -S— CH 2 CH 3
  • R 9 represents (i) hydrogen; (ii) C ⁇ alkyl [e.g. -CH ,
  • R 4 is aryl [e.g.
  • a further preferred group of compounds of the invention are compounds of formula (Ixa) in which:-W represents CH; X represents CR 2 and Y represents CR where R 2 and R3 form the group -CH 2 -CH 2 -CH 2 - ; Z represents CH; R 7 represents hydrogen; R ⁇ represents (i) hydrogen, (ii) C ⁇ alkyl
  • R 9 represents (i) hydrogen; (ii) C yalkyl [e.g. -CH3,
  • R 4 is aryl [e.g.
  • N-oxides, and their prodrugs, and their acid bioisosteres and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixa) and their N-oxides and their prodrugs, and their acid bioisosteres.
  • Another particular group of compounds of the invention are compounds of formula (Ix) wherein R 1 is a
  • p is zero, or an integer 1 ; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixb) and their N-oxides and their prodrugs, and their acid bioisosteres.
  • C-heteroaryl e.g. C ( N or ]
  • C-OR 4 e.g. C-OCH 3 , C-OCH,CH 3 , C-OCHF 2 , C ⁇ OCF 3 , C— O- // ⁇
  • halo e.g. chloro, fluoro
  • C ⁇ alkyl e.g. methyl
  • -OR 4 e.g. -OCH , -OCH 2 CH 3 ]
  • a preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W represents CH; X represents CH; Y represents CH; Z represents CH or C-CH3; R' represents hydrogen; R ⁇ represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) C ⁇ alkyl [e.g. methyl], (iv)
  • a further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W represents CH; X represents CH; Z represents CH; Y represents (i) C-C ⁇ allcyl [e.g. C-CH3,
  • C-Br C-Cl or C-F
  • C-haloalkyl e.g. C-CF3
  • C-heteroaryl e.g. C N or
  • R u represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii)
  • a further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W represents CH; X represents C-CH3, C-CH9CH3, C-CH(CH ) 2 , C-OCH3, C-OCH 2 CH 3 , C-Br or
  • Y represents C-CH3, C-CH 2 CH 3 , C-OCH3, C-Br, C-Cl, C-F, C or
  • a further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W represents CH; X represents CH; Y represents C-CH3; Z represents C-CH3; J represents hydrogen; p is zero or one; R iU represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) Cl-4alkyl [e.g. methyl], (iv)
  • a further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W represents CH; X represents CR 2 and Y represents CR? where R 2 and R? form the group -CH 2 -0-CH 2 -; Z represents CH; J represents hydrogen; p is zero or one; R 1 ⁇ represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) Cl-4alkyl [e.g. methyl], (iv) -OR 4 [e.g. -OCH3 or -OCH 2 CH 3 ] or
  • a further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W represents CH; X represents CR 2 and Y represents CR ⁇ where R 2 and R ⁇ form the group -CH 2 -CH 2 -CH 2 - ; Z represents CH; R7 represents hydrogen; p is zero or one; R iU represents (i) cyano, (ii) halo [e.g. chloro, fluoro], (iii) Cl-4alkyl [e.g. methyl], (iv) -OR 4 [e.g. -OCH3 or
  • Another particular group of compounds of the invention are compounds of formula (Ix) wherein R 1 is a
  • pharmaceutically acceptable salts and solvates e.g. hydrates
  • C-OR 4 [e.g. C-OCH 3 , C-OCH,CH 3 , C-OCHF, , C ⁇ OCF 3 , C— 0— P ,
  • a preferred group of compounds of the invention are compounds of formula (Ixc) in which:- W represents CH; X represents CH; Y represents CH; Z represents CH or C-CH3; R 7 represents
  • a further preferred group of compounds of the invention are compounds of formula (Ixc) in which:- W represents CH; X represents CH; Z represents CH; Y represents (i) C-Cj ⁇ alkyl [e.g. C-CH3,
  • C 7 — Cl C ([ 7 or ], (iii) C-CN, (iv) C-N0 2 , (v) C-halo [e.g. C-Br, C-Cl or C-F], (vi) C-haloalkyl [e.g. C-CF3], (vii) C-heteroaryl [e.g. or
  • C-OR 4 [e.g. C-OCH 3 , C ⁇ OCH,CH 3 , C-OCHF, , C-OCF, .
  • a further preferred group of compounds of the invention are compounds of formula (Ixc) in which:- W represents CH; X represents C-CH3, C-CH 2 CH 3 , C-CH(CH 3 ) 2 , C-OCH3, C-OCH 2 CH 3 , C-Br or
  • Y represents C-CH3, C-CH 2 CH 3 , C-OCH3, C-Br, C-Cl, C-F, C (' 7 or
  • Z represents CH
  • J represents hydrogen
  • q is zero
  • pharmaceutically acceptable salts and solvates e.g. hydrates of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.
  • a further preferred group of compounds of the invention are compounds of formula (Ixc) in which:-W represents CH; X represents CH; Y represents C-CH3; Z represents C-CH3; R' represents hydrogen;
  • a further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W represents CH; X represents CR 2 and Y represents CR ⁇ where R 2 and R ⁇ form the group
  • Z represents CH; represents hydrogen; represents a cyclopentyl cyclohexyl or cycloheptyl ring; q is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.
  • pharmaceutically acceptable salts and solvates e.g. hydrates
  • a further preferred group of compounds of the invention are compounds of formula (Ixb) in which:- W represents CH; X represents CR 2 and Y represents CR ⁇ where R 2 and R? form the group
  • Z represents CH;
  • R' represents hydrogen; represents a cyclopentyl cyclohexyl or cycloheptyl ring; q is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixc) and their N-oxides and their prodrugs, and their acid bioisosteres.
  • Another particular group of compounds of the invention are compounds of formula (Ix) wherein R 1 is a
  • W, X, Y, Z and X are as hereinbefore defined for compounds of formula (Ix),
  • r is zero or an integer one or two and R 1 ⁇ is alkyl or two R 1 ⁇ groups attached to the same carbon atom form an oxo group; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.
  • pharmaceutically acceptable salts and solvates e.g. hydrates
  • C-haloalkyl e.g. C-CF3
  • C-heteroaryl e.g. C V N or C V ]
  • N-S0 R 4 e.g. N-S0 2 CH 3 or N-S0 2 CH(CH 3 ) 2 ]; are preferred.
  • N-C( 0)OCH 2 CH ]; or (v) N-S0 R 4 [e.g. N-S0 2 CH or N-S0 2 CH(CH 3 ) 2 ] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.
  • N-S0 R 4 e.g. N-S0 2 CH or N-S0 2 CH(CH 3 ) 2
  • r is zero
  • pharmaceutically acceptable salts and solvates e.g. hydrates
  • a further preferred group of compounds of the invention are compounds of formula (Ixd) in which:- W represents CH; X represents CH; Z represents CH; Y represents (i) C-C ⁇ alkyl [e.g. C-CH3,
  • C-Br C-Cl or C-F
  • C-haloalkyl e.g. C-CF3
  • C-heteroaryl e.g. C ⁇ N or
  • N-C( 0)OCH CH 3 ]; or (v) N-S0 R 4 [e.g. N-S0 2 CH 3 or N-S0 2 CH(CH 3 ) 2 ] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.
  • pharmaceutically acceptable salts and solvates e.g. hydrates
  • a further preferred group of compounds of the invention are compounds of formula (Ixd) in which:- W represents CH; X represents C-CH3, C-CH 2 CH 3 , C-CH(CH 3 ) , C-OCH3, C-OCH 2 CH 3 , C-Br or
  • Y represents C-CH3, C-CH 2 CH 3 , C-OCH3, C-Br, C-Cl, C-F, or
  • X 1 is (i) O; (ii)
  • N-S0 2 CH(CH3) 2 ] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.
  • a further preferred group of compounds of the invention are compounds of formula (Ixd) in which: -W represents CH; X represents CH; Y represents C-CH3; Z represents C-CH3; R' represents hydrogen;
  • N-S0 2 R 4 [e.g. N-S0 2 CH3 or N-S0 2 CH(CH3) 2 ] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.
  • N-S0 2 CH(CH3) 2 ] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.
  • N-S0 2 CH(CH3) 2 ] and r is zero; and their corresponding N-oxides, and their prodrugs, and their acid bioisosteres; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (Ixd) and their N-oxides and their prodrugs, and their acid bioisosteres.
  • Particular compounds of the invention of formula (Ix) are selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (Al to A110) shown in Table 1 to the carbon atom (*C) in the heteroaryl moiety of one of the fragments (Bl to B168) shown in Table 2.
  • Particular compounds of the invention of formula (Ixa) are selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (Al to A110) shown in Table 1 to the carbon atom (*C) in the pyrazole ring of one of the fragments (Bl to B48, B74 to B107, B124 to B127, 130 to 142 or 144 to 150) shown in Table 2.
  • Particular compounds of the invention of formula (Ixb) are also selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (Al to Al 10) shown in Table 1 to the carbon atom (*C) in the five membered ring of one of the fragments (B63 to B73, B108 to Bl 14, B128 or B151) shown in Table 2.
  • Particular compounds of the invention of formula (Ixc) are selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (Al to Al 10) shown in Table 1 to the carbon atom (*C) in the five membered ring of one of the fragments (B56, B59 or B129) shown in Table 2.
  • Particular compounds of the invention of formula (Ixd) are selected from the compounds formed by joining the carbon atom (C*) of one of the benzoimidazole, imidazo[4,5-b]pyridine, imidazo[4,5-c]pyridine or imidazo[4,5-b]pyrazine fragments (Al to Al 10) shown in Table 1 to the carbon atom (*C) in the five membered ring of one of the fragments (B115 to B 123 or B 157) shown in Table 2.
  • the compound denoted as A9-B9 is the product of the combination of group A9 in Table 1 and B9 in Table 2, namely
  • Preferred compounds of formula (Ixa) of the invention for the inhibition of SYK are:-

Abstract

L'invention concerne des composés physiologiquement actifs représentés par la formule générale (Ix), des compositions qui renferment ces composés, leurs promédicaments, des sels ou solvates de ces composés acceptables sur le plan pharmaceutique et leurs promédicaments, ainsi que de nouveaux médicaments entrant dans le champ d'application de la formule (Ix) et des procédés pour leur préparation. Ces composés et compositions possèdent des propriétés pharmaceutiques intéressantes, notamment la capacité d'inhiber les kinases.
PCT/GB2002/004763 2001-10-26 2002-10-24 Benzimidazoles et analogues et leur utilisation comme inhibiteurs de proteines kinases WO2003035065A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2002334217A AU2002334217B2 (en) 2001-10-26 2002-10-24 Benzimidazoles and analogues and their use as protein kinases inhibitors
MXPA04003954A MXPA04003954A (es) 2001-10-26 2002-10-24 Bencimidazoles.
JP2003537632A JP5039268B2 (ja) 2001-10-26 2002-10-24 ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
IL16157602A IL161576A0 (en) 2001-10-26 2002-10-24 Benzimidazoles and analogues and their use as protein kinases inhibitors
CA2465247A CA2465247C (fr) 2001-10-26 2002-10-24 Benzimidazoles et analogues et leur utilisation comme inhibiteurs de proteines kinases
BR0213562-0A BR0213562A (pt) 2001-10-26 2002-10-24 Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
EP02801954A EP1441725A1 (fr) 2001-10-26 2002-10-24 Benzimidazoles et analogues et leur utilisation comme inhibiteurs de proteines kinases

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
FR0113868A FR2831537B1 (fr) 2001-10-26 2001-10-26 Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation
FR01/13868 2001-10-26
GB0206895.5 2002-03-22
GB0206893.0 2002-03-22
GB0206895A GB0206895D0 (en) 2002-03-22 2002-03-22 Chemical compounds
GB0206893A GB0206893D0 (en) 2002-03-22 2002-03-22 Chemical compounds
US39515102P 2002-07-11 2002-07-11
US39506002P 2002-07-11 2002-07-11
US60/395,060 2002-07-11
US60/395,151 2002-07-11

Publications (1)

Publication Number Publication Date
WO2003035065A1 true WO2003035065A1 (fr) 2003-05-01

Family

ID=27515325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/004763 WO2003035065A1 (fr) 2001-10-26 2002-10-24 Benzimidazoles et analogues et leur utilisation comme inhibiteurs de proteines kinases

Country Status (9)

Country Link
EP (1) EP1441725A1 (fr)
JP (1) JP5039268B2 (fr)
AU (1) AU2002334217B2 (fr)
BR (1) BR0213562A (fr)
CA (1) CA2465247C (fr)
IL (1) IL161576A0 (fr)
MX (1) MXPA04003954A (fr)
UY (1) UY27516A1 (fr)
WO (1) WO2003035065A1 (fr)

Cited By (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066629A2 (fr) * 2002-02-06 2003-08-14 Vertex Pharmaceuticals Incorporated Composes heteroaryles utiles en tant qu'inhibiteurs de gsk-3
WO2004000310A1 (fr) * 2002-06-20 2003-12-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicament pour traiter le syndrome de reponse inflammatoire systemique
WO2005002552A2 (fr) 2003-07-03 2005-01-13 Astex Therapeutics Limited Composes pharmaceutiques
WO2005002576A2 (fr) * 2003-07-03 2005-01-13 Astex Therapeutics Limited Composes pharmaceutiques
WO2005065686A1 (fr) * 2004-01-07 2005-07-21 Adipogen Pharmaceuticals Pty Limited Agents de modulation de la differenciation et utilisations associees
WO2005079791A1 (fr) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Derives d'acide thiophene-2-carboxylique (1h-benzimidazol-2 yl)-amide et composes associes utilises comme inhibiteurs de la tec kinase itk (kinase des lymphocites inductibles par l'interleukine -2) pour traiter une inflammation et des troubles immunologiques et allergiques
WO2005085230A1 (fr) * 2004-03-02 2005-09-15 Sanofi-Aventis Deutschland Gmbh Derive de 4-benzimidazol-2-yl-pyridazin-3-one, sa production et son utilisation dans des medicaments
WO2005085231A1 (fr) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Nouveaux derives 4-benzimidazol-2-ylpyridazin-3-one
WO2006049880A1 (fr) * 2004-10-27 2006-05-11 Janssen Pharmaceutica, N.V. Agents régulateurs de cannabinoïdes de type tétrahydropyridinylpyrazole
WO2006066914A2 (fr) * 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Derives carbamates heterocycliques, leur fabrication et leur utilisation comme agents pharmaceutiques
WO2006066913A2 (fr) * 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Derives benzamides, leur fabrication et leur utilisation comme agents pharmaceutiques
WO2006070195A1 (fr) * 2004-12-30 2006-07-06 Astex Therapeutics Limited Composes de pyrazole regulant l’activite de kinases cdk, gsk et aurora
WO2006070198A1 (fr) * 2004-12-30 2006-07-06 Astex Therapeutics Limited Derives pyrazoliques modulant l'activite des kinases cdk, gsk et aurora
WO2006080450A1 (fr) * 2005-01-27 2006-08-03 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur d’igf-1r
WO2006108489A1 (fr) * 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Derives aminopyrazole, leur fabrication et leur utilisation comme agents pharmaceutiques
WO2006108488A1 (fr) * 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Derives d'azole tricycliques, leur fabrication et leur utilisation en tant que principes pharmaceutiques
WO2006134318A1 (fr) * 2005-06-11 2006-12-21 Vernalis R & D Limited Dérivés de benzimidazole substitués au pyrazole pour une utilisation dans le traitement du cancer et de troubles auto-immuns
WO2007001939A1 (fr) * 2005-06-27 2007-01-04 Janssen Pharmaceutica N.V. Composes tetrahydro-pyranopyrazole presentant des activites de modulation de cannabinoïde
WO2007007778A1 (fr) 2005-07-13 2007-01-18 Taiho Pharmaceutical Co., Ltd. Composé de benzoimidazole capable d’inhiber la prostaglandine d synthétase
WO2007014707A1 (fr) * 2005-08-01 2007-02-08 F. Hoffmann-La Roche Ag Derives benzylamino heterocycliques, leurs procedes de fabrication et leur utilisation en tant qu'agents pharmaceutiques
WO2007017143A1 (fr) * 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Derives de l'azabenzimidazole, leur fabrication et leur utilisation en tant qu'agents anticancereux
JP2007505038A (ja) * 2003-09-08 2007-03-08 アベンティス・ファーマスーティカルズ・インコーポレイテツド チエノピラゾール
JP2007505908A (ja) * 2003-09-17 2007-03-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 縮合複素環式化合物
WO2007068465A1 (fr) * 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Dérivés tricycliques de lactame, leur fabrication et leur emploi en tant qu'agents pharmaceutiques
JP2007516186A (ja) * 2003-07-10 2007-06-21 アベンティス・ファーマ・ソシエテ・アノニム 置換テトラヒドロ−１Ｈ−ピラゾロ［３，４−ｃ］ピリジン、それらを含む組成物、及び使用
EP1809294A2 (fr) * 2004-09-21 2007-07-25 Synta Pharmaceuticals Corporation Composes pour l'inflammation et applications associees aux troubles immuns
WO2007083978A1 (fr) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Dérivés d'imidazopyridine inhibant l'activité de la protéine kinase, méthode de préparation de ces derniers et composition pharmaceutique les comprenant
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
US7309701B2 (en) 2002-11-19 2007-12-18 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
WO2008001115A2 (fr) * 2006-06-29 2008-01-03 Astex Therapeutics Limited Combinaisons pharmaceutiques
WO2008003857A1 (fr) * 2006-07-04 2008-01-10 Aventis Pharma S.A. Derives de pyrazolylbenzimidazole, compositions les contenant et leur utilisation
JP2008509138A (ja) * 2004-08-03 2008-03-27 ワイス 心臓血管疾患の治療に有用なインダゾール類
US7427616B2 (en) 2002-08-06 2008-09-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (TEK) activity
US7462613B2 (en) 2002-11-19 2008-12-09 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
EP2012779A2 (fr) * 2006-04-14 2009-01-14 Abbott Laboratories Procede de preparation d'indazolyl urees qui inhibent les recepteurs vanilloides de sous-type 1 (vr1)
WO2009103966A1 (fr) * 2008-02-19 2009-08-27 Cancer Research Technology Limited Composés de type bicyclylaryl-aryl-amine et leur utilisation
US7592340B2 (en) 2003-12-04 2009-09-22 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
WO2009138799A1 (fr) * 2008-05-14 2009-11-19 Astex Therapeutics Limited Utilisation thérapeutique de la 1-cyclopropyl-3-[3-(5-morpholin-4-ylméthyl-1h-benzoimidazol-2-yl)-lh-pyrazol-4-yl]-urée
WO2010080563A2 (fr) 2008-12-18 2010-07-15 Sanofi-Aventis Procédé de traitement d'une dégénérescence maculaire
US20110034441A1 (en) * 2009-08-10 2011-02-10 Epitherix, Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
AU2005200915B2 (en) * 2004-03-01 2011-04-14 Rottapharm Biotech S.R.L. Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production
US8058045B2 (en) 2007-10-05 2011-11-15 Cancer Research Technology Limited Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use
GB2482501A (en) * 2010-08-04 2012-02-08 Summit Corp Plc Novel compounds for use in the treatment of Clostridium Difficile and associated diseases
CN102372674A (zh) * 2010-08-17 2012-03-14 上海药明康德新药开发有限公司 医药中间体3-醛基-4-卤代吡唑的合成方法
US8252812B2 (en) 2009-08-10 2012-08-28 Samumed, Llc Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof
KR101190964B1 (ko) * 2003-07-03 2012-10-12 아스텍스 테라퓨틱스 리미티드 벤즈이미다졸 유도체 및 단백질 키나제로서의 그의 용도
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
AU2009266889B2 (en) * 2008-07-03 2013-05-02 Glaxosmithkline Llc Benzimidazoles and related analogs as sirtuin modulators
US8450340B2 (en) 2009-12-21 2013-05-28 Samumed, Llc 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US8486904B2 (en) 2007-10-01 2013-07-16 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
EP2615916A1 (fr) * 2010-09-16 2013-07-24 Merck Sharp & Dohme Corp. Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
US8569511B2 (en) 2011-04-01 2013-10-29 University Of Utah Research Foundation Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase
US8618128B1 (en) 2012-05-04 2013-12-31 Samumed, Llc 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2014008285A1 (fr) 2012-07-03 2014-01-09 Gilead Sciences, Inc. Inhibiteurs du virus de l'hépatite c
US8642598B2 (en) 2006-10-21 2014-02-04 Abbvie Inc. Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
US8658649B2 (en) 2006-09-11 2014-02-25 Sanofi Kinase inhibitor
US8664241B2 (en) 2012-04-04 2014-03-04 Samumed, Llc Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
US8710038B2 (en) 2004-09-17 2014-04-29 Exelixis, Inc. Pyrazole kinase modulators and methods of use
US8722903B2 (en) 2006-07-01 2014-05-13 Merck Patent Gmbh Indazole derivatives for the treatment of HSP9O-induced diseases
WO2014128465A1 (fr) * 2013-02-20 2014-08-28 Cancer Therapeutics Crc Pty Ltd Dérivés de 2-(hétéro)arylbenzimidazole et d'imidazopyridine comme inhibiteurs de l'asparagine méthyltransférase
US8829199B2 (en) 2009-08-07 2014-09-09 Chugai Seiyaku Kabushiki Kaisha Aminopyrazole derivative
WO2014145095A1 (fr) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Inhibiteurs macrocycliques et bicycliques du virus de l'hépatite c
US8884034B2 (en) 2009-07-08 2014-11-11 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US8933213B2 (en) 2011-06-16 2015-01-13 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
CN104334552A (zh) * 2012-05-31 2015-02-04 住友化学株式会社 稠合杂环化合物
US8975416B2 (en) 2008-12-02 2015-03-10 Summit Corporation Plc Antibacterial compounds
US8987308B2 (en) 2010-06-01 2015-03-24 Summit Corporation Plc Compounds for the treatment of Clostridium difficile-associated disease
CN104447701A (zh) * 2013-09-17 2015-03-25 广东东阳光药业有限公司 吡唑类衍生物及其用途
CN104640850A (zh) * 2012-10-26 2015-05-20 霍夫曼-拉罗奇有限公司 3,4-二取代的1h-吡唑和4,5-二取代的噻唑的syk抑制剂
US9040540B2 (en) 2011-11-09 2015-05-26 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
US9221793B2 (en) 2011-09-14 2015-12-29 Samumed, Llc Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors
WO2016040181A1 (fr) * 2014-09-08 2016-03-17 Samumed, Llc 3-1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040184A1 (fr) * 2014-09-08 2016-03-17 Samumed, Llc 3-3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040180A1 (fr) * 2014-09-08 2016-03-17 Samumed, Llc 3-1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040188A1 (fr) * 2014-09-08 2016-03-17 Samumed, Llc 3-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
US9351973B2 (en) 2011-09-22 2016-05-31 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9475807B2 (en) 2014-09-08 2016-10-25 Samumed, Llc 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof
US9493487B2 (en) 2014-09-08 2016-11-15 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof
WO2016202758A1 (fr) * 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Composés 2-(1h-pyrazol-1-yl)-1h-benzimidazole substitués
US9540370B2 (en) 2010-12-30 2017-01-10 Abbvie Deutschland Gmbh & Co., Kg. Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US9663503B2 (en) 2012-05-15 2017-05-30 Cancer Research Technology Limited 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
US9738638B2 (en) 2014-09-08 2017-08-22 Samumed, Llc 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof
US9758531B2 (en) 2014-09-08 2017-09-12 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof
US9908867B2 (en) 2013-01-08 2018-03-06 Samumed, Llc 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
US10065963B2 (en) 2015-11-06 2018-09-04 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
US10072004B2 (en) 2016-06-01 2018-09-11 Samumed, Llc Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo [4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
CN108546266A (zh) * 2018-07-25 2018-09-18 上海毕得医药科技有限公司 一种1,4,6,7-四氢吡喃[4,3-c]吡唑-3-羧酸的合成方法
US10085968B2 (en) 2009-12-04 2018-10-02 Sunovion Pharmaceuticals Inc. Multicyclic compounds and methods of use thereof
US10085984B2 (en) 2016-12-29 2018-10-02 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
US10100048B2 (en) 2010-09-27 2018-10-16 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10196403B2 (en) 2016-07-29 2019-02-05 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10391081B2 (en) 2013-12-27 2019-08-27 Chugai Seiyaku Kabushiki Kaisha FGFR gatekeeper mutant gene and drug targeting same
US10392383B2 (en) 2015-08-03 2019-08-27 Samumed, Llc 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10421743B2 (en) 2016-03-09 2019-09-24 Ctxt Pty Ltd Tetrahydroisoquinolines as PRMT5 inhibitors
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
US10479780B2 (en) 2015-06-17 2019-11-19 Chugai Seiyaku Kabushiki Kaisha Aminopyrazole derivatives
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10519167B2 (en) 2016-03-09 2019-12-31 Ctxt Pty Ltd 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies
US10538511B2 (en) 2016-12-29 2020-01-21 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
US10544139B2 (en) 2015-11-06 2020-01-28 Samumed, Llc Treatment of osteoarthritis
US10550096B2 (en) 2016-03-09 2020-02-04 Ctxt Pty Ltd Tetrahydroisoquinolines as PRMT5 inhibitors
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
US10647708B2 (en) 2014-09-03 2020-05-12 Ctxt Pty. Ltd Tetrahydroisoquinoline derived PRMT5-inhibitors
JP2020079276A (ja) * 2009-11-25 2020-05-28 日本たばこ産業株式会社 インドール化合物及びその医薬用途
US10696652B2 (en) 2008-01-22 2020-06-30 Vernalis (R&D) Ltd. Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
US10738057B2 (en) 2017-10-18 2020-08-11 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US10745380B2 (en) 2016-03-09 2020-08-18 Ctxt Pty Ltd Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies
US10752594B2 (en) 2013-03-14 2020-08-25 Sumitomo Dainippon Pharma Oncology, Inc. JAK1 and ALK2 inhibitors and methods for their use
WO2020150552A3 (fr) * 2019-01-17 2020-08-27 Samumed, Llc Procédés de traitement de troubles du cartilage par inhibition de clk et dyrk
US10758523B2 (en) 2016-11-07 2020-09-01 Samumed, Llc Single-dose, ready-to-use injectable formulations
US10780074B2 (en) 2017-08-02 2020-09-22 Sunovion Pharmaceuticals Inc. Compounds and uses thereof
US10787434B2 (en) 2016-03-09 2020-09-29 Ctxt Pty, Ltd Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies
AU2015373996B2 (en) * 2014-12-30 2020-10-08 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis B infections
US10806726B2 (en) 2016-10-21 2020-10-20 Samumed, Llc Methods of using indazole-3-carb oxamides and their use as Wnt/B-catenin signaling pathway inhibitors
US10815249B2 (en) 2018-02-16 2020-10-27 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
CN112239452A (zh) * 2020-10-14 2021-01-19 武汉尚赛光电科技有限公司 一种电子传输型杂蒽衍生物及其有机电致发光器件
US10961256B2 (en) 2016-03-09 2021-03-30 Ctxt Pty Ltd PRMT5 inhibitors
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
WO2021124155A1 (fr) * 2019-12-20 2021-06-24 Pfizer Inc. Dérivés de benzimidazole
US11077090B2 (en) 2016-07-29 2021-08-03 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
US11084825B2 (en) 2018-12-31 2021-08-10 Biomea Fusion, Llc Substituted pyridines as irreversible inhibitors of menin-MLL interaction
US11129807B2 (en) 2017-02-16 2021-09-28 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
US11136304B2 (en) 2019-03-14 2021-10-05 Sunovion Pharmaceuticals Inc. Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
US11186580B2 (en) 2018-09-05 2021-11-30 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor
CN114478511A (zh) * 2022-02-24 2022-05-13 中国药科大学 苯并恶唑类化合物及其制备方法、药物组合物和应用
US11352340B2 (en) 2016-01-05 2022-06-07 Incyte Corporation Pyridine and pyridimine compounds as PI3K-gamma inhibitors
US11738002B2 (en) 2020-04-14 2023-08-29 Sunovion Pharmaceuticals Inc. Methods of treating neurological and psychiatric disorders
RU2803284C1 (ru) * 2019-12-20 2023-09-12 Пфайзер Инк. Производные бензимидазола

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004189738A (ja) * 2002-11-29 2004-07-08 Nippon Nohyaku Co Ltd 置換アニリド誘導体、その中間体及び農園芸用薬剤並びにその使用方法
DE102006060598A1 (de) * 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
WO2009143039A2 (fr) * 2008-05-19 2009-11-26 Schering Corporation Composés hétérocycliques en tant qu'inhibiteurs du facteur ixa
CN101619058A (zh) * 2009-01-08 2010-01-06 上海交通大学 一种苯并咪唑-4-酰胺型衍生物
WO2012020725A1 (fr) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Dérivé hétérocyclique présentant un antagonisme pour le récepteur npy y5
CN104098513B (zh) * 2014-07-30 2016-08-24 天津市斯芬克司药物研发有限公司 一种吲唑化合物衍生物及其制备方法
KR20180005250A (ko) * 2015-05-21 2018-01-15 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Pad4 억제제로서의 벤조이미다졸 유도체
AR107030A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores aza-bencimidazol de pad4
WO2021060307A1 (fr) * 2019-09-25 2021-04-01 富士フイルム株式会社 Composé imidazopyridine ou sel de celui-ci, et composition pharmaceutique
WO2023234970A1 (fr) * 2022-06-01 2023-12-07 KUDA Therapeutics, Inc. Dérivés d'imidazopyridine et d'oxazolopyridine et leurs analogues, leurs procédés de préparation, procédés d'inhibition de la voie hif-1/2a et induction de la ferroptose

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2130030A1 (de) * 1971-06-18 1972-12-21 Bayer Ag Fungizide und bakterizide Mittel
DE2130029A1 (de) * 1971-06-18 1972-12-21 Bayer Ag Verfahren zur Herstellung von 2-[Pyrazolyl-(1)]-benzimidazolen
DE2263878A1 (de) * 1971-12-31 1973-07-05 Ciba Geigy Ag Verfahren zur herstellung heterocyklischer verbindungen
EP1006114A1 (fr) * 1997-04-11 2000-06-07 Grelan Pharmaceutical Co., Ltd. Derives de pyrazole et inhibiteurs de cox les renfermant
WO2001000610A1 (fr) * 1999-06-23 2001-01-04 Aventis Pharma Deutschland Gmbh Benzimidazoles substitues
WO2001002369A2 (fr) * 1999-07-02 2001-01-11 Agouron Pharmaceuticals, Inc. Composes d'indazole et compositions pharmaceutiques inhibant les proteines kinases, et procedes d'utilisation de ceux-ci
WO2001053268A2 (fr) * 2000-01-18 2001-07-26 Agouron Pharmaceuticals, Inc. Composes d'indazole, compositions pharmaceutiques, et methodes destines a la mediation ou a l'inhibition de la proliferation cellulaire
WO2003004488A1 (fr) * 2001-07-03 2003-01-16 Chiron Corporation Composes d'indazole benzimidazole utilises comme inhibiteurs de tyrosine et de serine/threonine kinase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69532817T2 (de) * 1994-11-10 2005-01-13 Millenium Pharmaceuticals, Inc., Cambridge Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2130030A1 (de) * 1971-06-18 1972-12-21 Bayer Ag Fungizide und bakterizide Mittel
DE2130029A1 (de) * 1971-06-18 1972-12-21 Bayer Ag Verfahren zur Herstellung von 2-[Pyrazolyl-(1)]-benzimidazolen
DE2263878A1 (de) * 1971-12-31 1973-07-05 Ciba Geigy Ag Verfahren zur herstellung heterocyklischer verbindungen
EP1006114A1 (fr) * 1997-04-11 2000-06-07 Grelan Pharmaceutical Co., Ltd. Derives de pyrazole et inhibiteurs de cox les renfermant
WO2001000610A1 (fr) * 1999-06-23 2001-01-04 Aventis Pharma Deutschland Gmbh Benzimidazoles substitues
WO2001002369A2 (fr) * 1999-07-02 2001-01-11 Agouron Pharmaceuticals, Inc. Composes d'indazole et compositions pharmaceutiques inhibant les proteines kinases, et procedes d'utilisation de ceux-ci
WO2001053268A2 (fr) * 2000-01-18 2001-07-26 Agouron Pharmaceuticals, Inc. Composes d'indazole, compositions pharmaceutiques, et methodes destines a la mediation ou a l'inhibition de la proliferation cellulaire
WO2003004488A1 (fr) * 2001-07-03 2003-01-16 Chiron Corporation Composes d'indazole benzimidazole utilises comme inhibiteurs de tyrosine et de serine/threonine kinase

Non-Patent Citations (49)

* Cited by examiner, † Cited by third party
Title
A.C.NEWTON, J. BIOL. CHEM., vol. 270, 1995, pages 28495 - 28498
A.M.CHENG, NATURE, vol. 378, 1995, pages 303 - 306
BEHR; FUSCO; JARBOE: "Heterocyclic Compounds, Pyrazoles, Pyrazolines, Pyrazolidines, indazoles and condensed rings", 1967, J. WILEY
C.CHAN, ANN. REV. IMMUNOL., vol. 12, 1994, pages 555 - 592
CHEM. PHARM. BULL., vol. 31, no. 4, 1983, pages 1228 - 1234
D.H.CHU ET AL., IMMUNOLOGICAL REVIEWS, vol. 165, 1998, pages 167 - 180
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002204302, Database accession no. 1995:505008 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002204303, Database accession no. 1975:97992 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002204304, Database accession no. 1994:605262 *
DATABASE CROSSFIRE BEILSTEIN Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002204305 *
ESSASSI E M ET AL: "Synthèse et hétérocyclisation des (pyrazolyl-3(5))-2-benzimidazoles en catalyse de transfert de phase", BULLETIN DES SOCIÉTÉS CHIMIQUES BELGES, vol. 96, no. 1, 1987, pages 63 - 67, XP008005414 *
F.YANAGA ET AL., BIOCHEM. J., vol. 311, 1995, pages 471 - 478
FINAR I L ET AL: "The preparation and some reactions of 4-formyl-1-phenyl- pyrazoles", JOURNAL OF THE CHEMICAL SOCIETY, 1961, pages 2733 - 2738, XP002204301 *
FOLKMAN, NATURE MED., vol. 1, 1995, pages 27 - 31
G. R. NEWKOME; W.W. PAUDLER: "Comtemporary Heterocyclic Chemistry, Syntheses, Reactions and Applications", 1982, J. WILEY
GRAHAM: "Theoretical Studies Applied To Drug Design:ab initio Electronic Distributions In Bioisosteres", THEOCHEM, vol. 343, 1995, pages 105 - 109, XP000985671
HUBERT A J ET AL: "Thermolyse von v-Triazolyl-Derivaten", CHEMISCHE BERICHTE, vol. 103, no. 12, 7 December 1970 (1970-12-07), pages 3811 - 3816, XP002204297 *
J. CHEM. RES., SYNOP., no. 7, 1994, pages 286 - 287 *
J. INDIAN CHEM. SOC., vol. 70, no. 11-12, 1993, pages 1035 - 1042 *
J. ORG. CHEM., vol. 47, no. 2, 1982, pages 214 - 221
J.PINES, TRENDS IN BIOCHEMICAL SCIENCES, vol. 18, 1995, pages 195 - 197
JEKUNEN ET AL., CANCER TREATMENT REV., vol. 23, 1997, pages 263 - 286
JOSHI K C ET AL: "Investigation of the reactions of 2-hydrazino-benzimidazoles with beta-diketones: synthesis of 2-(3,5-disubstituted-1H-pyrazol-1-yl) benzimidazoles", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 25, no. 6, 1988, pages 1641 - 1643, XP002204298 *
KHIM. FARM. ZH., vol. 7, no. 6, 1973, pages 18 *
KHIM. GETEROTSIKL. SOEDIN., no. 12, 1974, pages 1690 - 1694 *
KUNIO SEKI ET AL., CHEM. PHARM. BULL., vol. 32, no. 4, 1984, pages 1568 - 1577
L.R.HENDRICKS-TAYLOR ET AL., J.BIOL. CHEM, vol. 272, 1997, pages 1363 - 1367
LEE C.G.; HEIJN M. ET AL., CANCER RESEARCH, vol. 60, no. 19, 2000, pages 5565 - 70
LIPINSKI: "Bioisosterism In Drug Design", ANNUAL REPORTS IN MEDICINAL CHEMISTRY, vol. 21, 1986, pages 283
M.FARIS ET AL., J.EXP. MED., vol. 179, 1994, pages 1923 - 1931
M.ISHIAI ET AL., IMMUNITY, vol. 10, 1999, pages 117 - 125
M.RETH, NATURE, vol. 338, 1989, pages 383 - 384
MILLAUER ET AL., CANCER RESEARCH, vol. 56, 1996, pages 1615 - 1620
N.S.VAN OERS; A.WEISS, SEMINARS IN IMMUNOLOGY, vol. 7, 1995, pages 227 - 236
P.S.COSTELLO, ONCOGENE, vol. 13, 1996, pages 2595 - 2605
PRESTON: "Heterocyclic Compounds, Benzimidazoles and congeneric tricyclic compounds", 1981, J. WILEY
R.C.LAROCK: "Comprehensive Organic Transformations", 1989, VCH PUBLISHERS
S.IWASHITA; M.KOBAYASHI, CELLULAR SIGNALLING, vol. 4, 1992, pages 123 - 132
S.K.HANKS; T.HUNTER, FASEB. J., vol. 9, 1995, pages 576 - 596
S.YOUSEFI ET AL., J. EXP. MED., vol. 183, 1996, pages 1407 - 1414
See also references of EP1441725A1
SENGA K ET AL: "Synthesis of pyrazolo[1',5':1,2]-1,3,5-triazino[5,6-a] benzimidazoles", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 12, no. 5, October 1975 (1975-10-01), pages 899 - 901, XP002204300 *
SINGH S P ET AL: "Formation and dehydration of a series of 5-hydroxy-5-trifluoromethyl- 4,5-dihydropyrazoles", JOURNAL OF FLUORINE CHEMISTRY, vol. 94, no. 2, 5 April 1999 (1999-04-05), pages 199 - 203, XP004163162 *
SOOS T ET AL: "Novel thermal rearrangement of fused diaryl-v-triazolium salts to neutral indazole derivatives. Fused azolium salts. 16", JOURNAL OF ORGANIC CHEMISTRY, vol. 62, no. 4, February 1997 (1997-02-01), pages 1136 - 1138, XP002204296 *
STRAWN ET AL., CANCER RESEARCH, vol. 56, 1996, pages 3540 - 3545
T.W. GREENE; P.G.M.WUTS: "Protective Groups in Organic Chemistry", 1991, JOHN WILEY AND SONS
TAGAKI K ET AL: "Synthesis of pyrimidino[4,5-b][1,5]benzodiazepin-2-ones and pyrimidino[1,6-a]benzimidazol-1-ones from 4-ethoxycarbonylamino-1H- 1,5-benzodiazpine-3-carbonitrile via 4-(2-aminoanilino)pyrimidin-2(1H)-one-5- carbonitriles", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 23, no. 5, 1986, pages 1443 - 1449, XP002204299 *
YUN: "Application Of Bioisosterism To New Drug Design", HWAHAK SEKYE, vol. 33, 1993, pages 576 - 579
ZHAO: "Bioisosteric Replacement And Development Of Lead Compounds In Drug Design", HUAXUE TONGBAO, 1995, pages 34 - 38

Cited By (298)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066629A2 (fr) * 2002-02-06 2003-08-14 Vertex Pharmaceuticals Incorporated Composes heteroaryles utiles en tant qu'inhibiteurs de gsk-3
WO2003066629A3 (fr) * 2002-02-06 2003-10-30 Vertex Pharma Composes heteroaryles utiles en tant qu'inhibiteurs de gsk-3
WO2004000310A1 (fr) * 2002-06-20 2003-12-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicament pour traiter le syndrome de reponse inflammatoire systemique
US7427616B2 (en) 2002-08-06 2008-09-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (TEK) activity
US7309701B2 (en) 2002-11-19 2007-12-18 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
US7462613B2 (en) 2002-11-19 2008-12-09 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
WO2005002576A3 (fr) * 2003-07-03 2005-06-16 Astex Technology Ltd Composes pharmaceutiques
EP2305250A1 (fr) 2003-07-03 2011-04-06 Astex Therapeutics Limited Dérivés de la benzimidazole et leur utilisation en tant qu'inhibiteurs de proteine kinases
JP2007516194A (ja) * 2003-07-03 2007-06-21 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2005002552A2 (fr) 2003-07-03 2005-01-13 Astex Therapeutics Limited Composes pharmaceutiques
KR101190964B1 (ko) * 2003-07-03 2012-10-12 아스텍스 테라퓨틱스 리미티드 벤즈이미다졸 유도체 및 단백질 키나제로서의 그의 용도
JP4833059B2 (ja) * 2003-07-03 2011-12-07 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2005002576A2 (fr) * 2003-07-03 2005-01-13 Astex Therapeutics Limited Composes pharmaceutiques
US7977477B2 (en) 2003-07-03 2011-07-12 Astex Therapeutics, Limited Benzimidazole derivatives and their use as protein kinase inhibitors
WO2005002552A3 (fr) * 2003-07-03 2005-06-16 Astex Technology Ltd Composes pharmaceutiques
AU2004253338B2 (en) * 2003-07-03 2010-02-18 Astex Therapeutics Limited Benzimidazole derivatives and their use as protein kinases inhibitors
JP4740841B2 (ja) * 2003-07-10 2011-08-03 アベンティス・ファーマ・ソシエテ・アノニム 置換テトラヒドロ−１Ｈ−ピラゾロ［３，４−ｃ］ピリジン、それらを含む組成物、及び使用
JP2007516186A (ja) * 2003-07-10 2007-06-21 アベンティス・ファーマ・ソシエテ・アノニム 置換テトラヒドロ−１Ｈ−ピラゾロ［３，４−ｃ］ピリジン、それらを含む組成物、及び使用
JP2007505038A (ja) * 2003-09-08 2007-03-08 アベンティス・ファーマスーティカルズ・インコーポレイテツド チエノピラゾール
JP2007505908A (ja) * 2003-09-17 2007-03-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 縮合複素環式化合物
US7592340B2 (en) 2003-12-04 2009-09-22 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
WO2005065686A1 (fr) * 2004-01-07 2005-07-21 Adipogen Pharmaceuticals Pty Limited Agents de modulation de la differenciation et utilisations associees
WO2005079791A1 (fr) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Derives d'acide thiophene-2-carboxylique (1h-benzimidazol-2 yl)-amide et composes associes utilises comme inhibiteurs de la tec kinase itk (kinase des lymphocites inductibles par l'interleukine -2) pour traiter une inflammation et des troubles immunologiques et allergiques
AU2005200915B2 (en) * 2004-03-01 2011-04-14 Rottapharm Biotech S.R.L. Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production
US7754713B2 (en) 2004-03-02 2010-07-13 Aventis Pharma S.A. 4-benzimidazol-2-ylpyridazin-3-one derivatives
JP4792455B2 (ja) * 2004-03-02 2011-10-12 アバンテイス・フアルマ・エス・アー 新規４−ベンゾイミダゾール−２−イルピリダジン−３−オン誘導体
WO2005085231A1 (fr) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Nouveaux derives 4-benzimidazol-2-ylpyridazin-3-one
WO2005085230A1 (fr) * 2004-03-02 2005-09-15 Sanofi-Aventis Deutschland Gmbh Derive de 4-benzimidazol-2-yl-pyridazin-3-one, sa production et son utilisation dans des medicaments
US7470689B2 (en) 2004-03-02 2008-12-30 Aventis Pharma S.A. 4-benzimidazol-2-ylpyridazin-3-one derivatives
JP2008509138A (ja) * 2004-08-03 2008-03-27 ワイス 心臓血管疾患の治療に有用なインダゾール類
US8710038B2 (en) 2004-09-17 2014-04-29 Exelixis, Inc. Pyrazole kinase modulators and methods of use
US8524756B2 (en) 2004-09-21 2013-09-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US7709518B2 (en) 2004-09-21 2010-05-04 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
EP1809294A2 (fr) * 2004-09-21 2007-07-25 Synta Pharmaceuticals Corporation Composes pour l'inflammation et applications associees aux troubles immuns
EP1809294A4 (fr) * 2004-09-21 2008-08-06 Synta Pharmaceuticals Corp Composes pour l'inflammation et applications associees aux troubles immuns
US8314134B2 (en) 2004-09-21 2012-11-20 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
AU2005302697B2 (en) * 2004-10-27 2012-09-13 Janssen Pharmaceutica, N.V. Tetrahydro pyridinyl pyrazole cannabinoid modulators
JP4942660B2 (ja) * 2004-10-27 2012-05-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ テトラヒドロピリジニルピラゾールカンナビノイドモジュレーター
WO2006049880A1 (fr) * 2004-10-27 2006-05-11 Janssen Pharmaceutica, N.V. Agents régulateurs de cannabinoïdes de type tétrahydropyridinylpyrazole
JP2008518008A (ja) * 2004-10-27 2008-05-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ テトラヒドロピリジニルピラゾールカンナビノイドモジュレーター
US7618964B2 (en) 2004-12-23 2009-11-17 Hoffmann-La Roche Inc. Benzamide derivatives, their manufacture and use as pharmaceutical agents
JP2008525355A (ja) * 2004-12-23 2008-07-17 エフ．ホフマン−ラ ロシュ アーゲー ベンズアミド誘導体、これらの製造及び医薬剤としての使用。
JP2008521768A (ja) * 2004-12-23 2008-06-26 エフ．ホフマン−ラ ロシュ アーゲー ヘテロ環式カルバミン酸誘導体、それらの製造及び医薬品としての使用
US7786113B2 (en) 2004-12-23 2010-08-31 Hoffman-La Roche Inc. Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents
WO2006066914A3 (fr) * 2004-12-23 2006-10-12 Hoffmann La Roche Derives carbamates heterocycliques, leur fabrication et leur utilisation comme agents pharmaceutiques
WO2006066913A2 (fr) * 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Derives benzamides, leur fabrication et leur utilisation comme agents pharmaceutiques
WO2006066914A2 (fr) * 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Derives carbamates heterocycliques, leur fabrication et leur utilisation comme agents pharmaceutiques
WO2006066913A3 (fr) * 2004-12-23 2006-09-21 Hoffmann La Roche Derives benzamides, leur fabrication et leur utilisation comme agents pharmaceutiques
EP2395000A1 (fr) 2004-12-30 2011-12-14 Astex Therapeutics Limited Composés de benzimidazole régulant l' activite de kinases CDK, GSK et aurora
US8778936B2 (en) 2004-12-30 2014-07-15 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
WO2006070195A1 (fr) * 2004-12-30 2006-07-06 Astex Therapeutics Limited Composes de pyrazole regulant l’activite de kinases cdk, gsk et aurora
WO2006070198A1 (fr) * 2004-12-30 2006-07-06 Astex Therapeutics Limited Derives pyrazoliques modulant l'activite des kinases cdk, gsk et aurora
TWI427077B (zh) * 2004-12-30 2014-02-21 Astex Therapeutics Ltd 吡唑化合物及其用途和含有彼之藥學組成物
JP2009108069A (ja) * 2005-01-27 2009-05-21 Kyowa Hakko Kirin Co Ltd Ｉｇｆ−１ｒ阻害剤
US7605272B2 (en) 2005-01-27 2009-10-20 Kyowa Hakko Kirin Co., Ltd. IGF-1R inhibitor
WO2006080450A1 (fr) * 2005-01-27 2006-08-03 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur d’igf-1r
WO2006108488A1 (fr) * 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Derives d'azole tricycliques, leur fabrication et leur utilisation en tant que principes pharmaceutiques
US7462639B2 (en) 2005-04-14 2008-12-09 Hoffmann-La Roche Inc. Aminopyrazole derivatives
WO2006108489A1 (fr) * 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Derives aminopyrazole, leur fabrication et leur utilisation comme agents pharmaceutiques
WO2006134318A1 (fr) * 2005-06-11 2006-12-21 Vernalis R & D Limited Dérivés de benzimidazole substitués au pyrazole pour une utilisation dans le traitement du cancer et de troubles auto-immuns
WO2007001939A1 (fr) * 2005-06-27 2007-01-04 Janssen Pharmaceutica N.V. Composes tetrahydro-pyranopyrazole presentant des activites de modulation de cannabinoïde
WO2007007778A1 (fr) 2005-07-13 2007-01-18 Taiho Pharmaceutical Co., Ltd. Composé de benzoimidazole capable d’inhiber la prostaglandine d synthétase
US7951956B2 (en) 2005-07-13 2011-05-31 Taiho Pharmaceuticals Co., Ltd. Benzoimidazole compound capable of inhibiting prostaglandin D synthetase
JP2009502843A (ja) * 2005-07-29 2009-01-29 エフ．ホフマン−ラ ロシュ アーゲー アザベンズイミダゾール誘導体、それらの製造、及び抗癌剤としての使用
WO2007017143A1 (fr) * 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Derives de l'azabenzimidazole, leur fabrication et leur utilisation en tant qu'agents anticancereux
US7776878B2 (en) 2005-08-01 2010-08-17 Hoffmann-La Roche Inc. Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
WO2007014707A1 (fr) * 2005-08-01 2007-02-08 F. Hoffmann-La Roche Ag Derives benzylamino heterocycliques, leurs procedes de fabrication et leur utilisation en tant qu'agents pharmaceutiques
WO2007068465A1 (fr) * 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Dérivés tricycliques de lactame, leur fabrication et leur emploi en tant qu'agents pharmaceutiques
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
WO2007083978A1 (fr) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Dérivés d'imidazopyridine inhibant l'activité de la protéine kinase, méthode de préparation de ces derniers et composition pharmaceutique les comprenant
JP2009533474A (ja) * 2006-04-14 2009-09-17 アボット・ラボラトリーズ バニロイドサブタイプ１（ｖｒ１）受容体を阻害するインダゾリルウレアの製造方法
EP2012779A4 (fr) * 2006-04-14 2010-11-24 Abbott Lab Procede de preparation d'indazolyl urees qui inhibent les recepteurs vanilloides de sous-type 1 (vr1)
US8519186B2 (en) 2006-04-14 2013-08-27 Abbvie Inc. Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype 1 (VR1) receptors
EP2012779A2 (fr) * 2006-04-14 2009-01-14 Abbott Laboratories Procede de preparation d'indazolyl urees qui inhibent les recepteurs vanilloides de sous-type 1 (vr1)
WO2008001115A2 (fr) * 2006-06-29 2008-01-03 Astex Therapeutics Limited Combinaisons pharmaceutiques
WO2008001115A3 (fr) * 2006-06-29 2008-03-13 Astex Therapeutics Ltd Combinaisons pharmaceutiques
US8435970B2 (en) 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
US8722903B2 (en) 2006-07-01 2014-05-13 Merck Patent Gmbh Indazole derivatives for the treatment of HSP9O-induced diseases
US9126969B2 (en) 2006-07-04 2015-09-08 Aventis Pharma S.A. Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof
WO2008003857A1 (fr) * 2006-07-04 2008-01-10 Aventis Pharma S.A. Derives de pyrazolylbenzimidazole, compositions les contenant et leur utilisation
FR2903406A1 (fr) * 2006-07-04 2008-01-11 Aventis Pharma Sa Derives de pyrazolylbenzimidazole,compositions les contenant et utilisation
US8658649B2 (en) 2006-09-11 2014-02-25 Sanofi Kinase inhibitor
US9856234B2 (en) 2006-10-21 2018-01-02 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
US8642598B2 (en) 2006-10-21 2014-02-04 Abbvie Inc. Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
US8895529B2 (en) 2007-10-01 2014-11-25 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
US8486904B2 (en) 2007-10-01 2013-07-16 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
US8058045B2 (en) 2007-10-05 2011-11-15 Cancer Research Technology Limited Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use
US8367658B2 (en) 2007-10-05 2013-02-05 Cancer Research Technology Limited Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use
US10696652B2 (en) 2008-01-22 2020-06-30 Vernalis (R&D) Ltd. Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
WO2009103966A1 (fr) * 2008-02-19 2009-08-27 Cancer Research Technology Limited Composés de type bicyclylaryl-aryl-amine et leur utilisation
US8530468B2 (en) 2008-02-19 2013-09-10 Cancer Research Technology Limited Bicyclylaryl-aryl-amine compounds and their use
WO2009138799A1 (fr) * 2008-05-14 2009-11-19 Astex Therapeutics Limited Utilisation thérapeutique de la 1-cyclopropyl-3-[3-(5-morpholin-4-ylméthyl-1h-benzoimidazol-2-yl)-lh-pyrazol-4-yl]-urée
US8846947B2 (en) 2008-07-03 2014-09-30 Glaxosmithkline Llc Benzimidazoles and related analogs as sirtuin modulators
AU2009266889B2 (en) * 2008-07-03 2013-05-02 Glaxosmithkline Llc Benzimidazoles and related analogs as sirtuin modulators
US9314456B2 (en) 2008-12-02 2016-04-19 Summit Therapeutics Plc Antibacterial compounds
US8975416B2 (en) 2008-12-02 2015-03-10 Summit Corporation Plc Antibacterial compounds
US9763925B2 (en) 2008-12-02 2017-09-19 Summit Therapeutics Plc Antibacterial compounds
WO2010080563A2 (fr) 2008-12-18 2010-07-15 Sanofi-Aventis Procédé de traitement d'une dégénérescence maculaire
EP2653193A1 (fr) 2008-12-18 2013-10-23 Sanofi Procédé pour le traitement de la dégénération maculaire
US9782382B2 (en) 2009-07-08 2017-10-10 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
US8884034B2 (en) 2009-07-08 2014-11-11 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
US9434718B2 (en) 2009-07-08 2016-09-06 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
US9102692B2 (en) 2009-08-07 2015-08-11 Chugai Seiyaku Kabushiki Kaisha Aminopyrazole derivative
US8829199B2 (en) 2009-08-07 2014-09-09 Chugai Seiyaku Kabushiki Kaisha Aminopyrazole derivative
US8703794B2 (en) 2009-08-10 2014-04-22 Samumed, Llc Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
US9381192B2 (en) 2009-08-10 2016-07-05 Samumed, Llc Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
US8604052B2 (en) 2009-08-10 2013-12-10 Samumed, Llc Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof
US8252812B2 (en) 2009-08-10 2012-08-28 Samumed, Llc Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof
US20110034441A1 (en) * 2009-08-10 2011-02-10 Epitherix, Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
US10016406B2 (en) 2009-08-10 2018-07-10 Samumed, Llc Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof
US9090613B2 (en) 2009-08-10 2015-07-28 Samumed, Llc Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
US9763927B2 (en) 2009-08-10 2017-09-19 Samumed, Llc Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
JP2020079276A (ja) * 2009-11-25 2020-05-28 日本たばこ産業株式会社 インドール化合物及びその医薬用途
US10894033B2 (en) 2009-12-04 2021-01-19 Sunovion Pharmaceuticals Inc. Multicyclic compounds and methods of use thereof
US10085968B2 (en) 2009-12-04 2018-10-02 Sunovion Pharmaceuticals Inc. Multicyclic compounds and methods of use thereof
US9446035B2 (en) 2009-12-21 2016-09-20 Samumed, Llc 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10105370B2 (en) 2009-12-21 2018-10-23 Samumed, Llc 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US9855272B2 (en) 2009-12-21 2018-01-02 Samumed, Llc 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US8901150B2 (en) 2009-12-21 2014-12-02 Samumed, Llc 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US8450340B2 (en) 2009-12-21 2013-05-28 Samumed, Llc 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US8846714B2 (en) 2009-12-21 2014-09-30 Samumed, Llc 1H-pyrazolo[3,4-β]pyridines and therapeutic uses thereof
US9067939B2 (en) 2009-12-21 2015-06-30 Samumed, Llc 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US9278091B2 (en) 2010-06-01 2016-03-08 Summit Therapeutics Plc Compounds for the treatment of Clostridium difficile associated disease
US8987308B2 (en) 2010-06-01 2015-03-24 Summit Corporation Plc Compounds for the treatment of Clostridium difficile-associated disease
GB2482501A (en) * 2010-08-04 2012-02-08 Summit Corp Plc Novel compounds for use in the treatment of Clostridium Difficile and associated diseases
CN102372674A (zh) * 2010-08-17 2012-03-14 上海药明康德新药开发有限公司 医药中间体3-醛基-4-卤代吡唑的合成方法
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2615916A4 (fr) * 2010-09-16 2014-04-09 Merck Sharp & Dohme Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
EP2615916A1 (fr) * 2010-09-16 2013-07-24 Merck Sharp & Dohme Corp. Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
US10100048B2 (en) 2010-09-27 2018-10-16 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9540370B2 (en) 2010-12-30 2017-01-10 Abbvie Deutschland Gmbh & Co., Kg. Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US8569511B2 (en) 2011-04-01 2013-10-29 University Of Utah Research Foundation Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase
US8933213B2 (en) 2011-06-16 2015-01-13 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
WO2013026516A1 (fr) 2011-08-23 2013-02-28 Merck Patent Gmbh Composés hétéroaromatiques bicycliques
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
US10464924B2 (en) 2011-09-14 2019-11-05 Samumed, Llc Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors
US9221793B2 (en) 2011-09-14 2015-12-29 Samumed, Llc Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors
US9802916B2 (en) 2011-09-14 2017-10-31 Samumed, Llc Indazole-3-carboxamides and their use as Wnt/beta-catenin signaling pathway inhibitors
US11780823B2 (en) 2011-09-14 2023-10-10 Biosplice Therapeutics, Inc. Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors
US11066388B2 (en) 2011-09-14 2021-07-20 Biosplice Therapeutics, Inc. Indazole-3-carboxamides and their use as WNT/B-catenin signaling pathway inhibitors
US9351973B2 (en) 2011-09-22 2016-05-31 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
US9844553B2 (en) 2011-09-22 2017-12-19 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
US9765059B2 (en) 2011-11-09 2017-09-19 Cancer Research Technology Limited 5-(Pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
US9403797B2 (en) 2011-11-09 2016-08-02 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
US9040540B2 (en) 2011-11-09 2015-05-26 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
US10947228B2 (en) 2012-04-04 2021-03-16 Samumed, Llc Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
US11697649B2 (en) 2012-04-04 2023-07-11 Biosplice Therapeutics, Inc. Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
US10407425B2 (en) 2012-04-04 2019-09-10 Samumed, Llc Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
US8987298B2 (en) 2012-04-04 2015-03-24 Samumed, Llc Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
US9994563B2 (en) 2012-04-04 2018-06-12 Samumed, Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
US9199991B2 (en) 2012-04-04 2015-12-01 Samumed, Llc Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof
US8664241B2 (en) 2012-04-04 2014-03-04 Samumed, Llc Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
US8673936B2 (en) 2012-04-04 2014-03-18 Samumed, Llc Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9233104B2 (en) 2012-05-04 2016-01-12 Samumed, Llc 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US9012472B2 (en) 2012-05-04 2015-04-21 Samumed, Llc 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US9586977B2 (en) 2012-05-04 2017-03-07 Samumed, Llc 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US8883822B2 (en) 2012-05-04 2014-11-11 Samumed, Llc 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US8618128B1 (en) 2012-05-04 2013-12-31 Samumed, Llc 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10342788B2 (en) 2012-05-04 2019-07-09 Samumed, Llc 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10071086B2 (en) 2012-05-04 2018-09-11 Samumed, Llc 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US11787792B2 (en) 2012-05-15 2023-10-17 Cancer Research Technology Limited 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-carbonitrile and therapeutic uses thereof
US9663503B2 (en) 2012-05-15 2017-05-30 Cancer Research Technology Limited 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
US10259806B2 (en) 2012-05-15 2019-04-16 Cancer Research Technology Limited 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
CN104334552A (zh) * 2012-05-31 2015-02-04 住友化学株式会社 稠合杂环化合物
CN104334552B (zh) * 2012-05-31 2016-08-31 住友化学株式会社 稠合杂环化合物
WO2014008285A1 (fr) 2012-07-03 2014-01-09 Gilead Sciences, Inc. Inhibiteurs du virus de l'hépatite c
EP3159345A1 (fr) 2012-07-03 2017-04-26 Gilead Sciences, Inc. Inhibiteurs du virus de l'hépatite c
EP3825312A1 (fr) 2012-07-03 2021-05-26 Gilead Pharmasset LLC Intermédiaires dans la synthèse d'inhibiteurs du virus de l'hépatite c
EP3492464A1 (fr) 2012-07-03 2019-06-05 Gilead Sciences, Inc. Intermédiaires dans la synthèse d'inhibiteurs du virus de l'hépatite c
CN104640850A (zh) * 2012-10-26 2015-05-20 霍夫曼-拉罗奇有限公司 3,4-二取代的1h-吡唑和4,5-二取代的噻唑的syk抑制剂
US10654832B2 (en) 2013-01-08 2020-05-19 Samumed, Llc 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof
US10183929B2 (en) 2013-01-08 2019-01-22 Samumed, Llc 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof
US9908867B2 (en) 2013-01-08 2018-03-06 Samumed, Llc 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof
US9856252B2 (en) 2013-02-20 2018-01-02 Cancer Therapeutics Crc Pty Ltd 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase
WO2014128465A1 (fr) * 2013-02-20 2014-08-28 Cancer Therapeutics Crc Pty Ltd Dérivés de 2-(hétéro)arylbenzimidazole et d'imidazopyridine comme inhibiteurs de l'asparagine méthyltransférase
US10752594B2 (en) 2013-03-14 2020-08-25 Sumitomo Dainippon Pharma Oncology, Inc. JAK1 and ALK2 inhibitors and methods for their use
WO2014145095A1 (fr) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Inhibiteurs macrocycliques et bicycliques du virus de l'hépatite c
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN104447701A (zh) * 2013-09-17 2015-03-25 广东东阳光药业有限公司 吡唑类衍生物及其用途
US10391081B2 (en) 2013-12-27 2019-08-27 Chugai Seiyaku Kabushiki Kaisha FGFR gatekeeper mutant gene and drug targeting same
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
US10647708B2 (en) 2014-09-03 2020-05-12 Ctxt Pty. Ltd Tetrahydroisoquinoline derived PRMT5-inhibitors
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
US10023572B2 (en) 2014-09-08 2018-07-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
US9758531B2 (en) 2014-09-08 2017-09-12 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof
US10052331B2 (en) 2014-09-08 2018-08-21 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof
US9475825B2 (en) 2014-09-08 2016-10-25 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof
US9889140B2 (en) 2014-09-08 2018-02-13 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof
US10131677B2 (en) 2014-09-08 2018-11-20 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof
WO2016040181A1 (fr) * 2014-09-08 2016-03-17 Samumed, Llc 3-1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
US9844536B2 (en) 2014-09-08 2017-12-19 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof
WO2016040184A1 (fr) * 2014-09-08 2016-03-17 Samumed, Llc 3-3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
US9475807B2 (en) 2014-09-08 2016-10-25 Samumed, Llc 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof
WO2016040180A1 (fr) * 2014-09-08 2016-03-17 Samumed, Llc 3-1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
US9493487B2 (en) 2014-09-08 2016-11-15 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof
US10202377B2 (en) 2014-09-08 2019-02-12 Samumed, Llc 3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof
US9763951B2 (en) 2014-09-08 2017-09-19 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof
US10206929B2 (en) 2014-09-08 2019-02-19 Samumed, Llc 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
US10081631B2 (en) 2014-09-08 2018-09-25 Samumed, Llc 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof
US9738638B2 (en) 2014-09-08 2017-08-22 Samumed, Llc 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof
US9657016B2 (en) 2014-09-08 2017-05-23 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
US10526347B2 (en) 2014-09-08 2020-01-07 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof
US9546185B2 (en) 2014-09-08 2017-01-17 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof
US10280166B2 (en) 2014-09-08 2019-05-07 Samumed, Llc 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof
WO2016040188A1 (fr) * 2014-09-08 2016-03-17 Samumed, Llc 3-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
US10596154B2 (en) 2014-09-08 2020-03-24 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof
US9540398B2 (en) 2014-09-08 2017-01-10 Samumed, Llc 3-(1h-imidazo[4,5-C]pyridin-2-yl)-1h-pyrazolo[3,4-C]pyridine and therapeutic uses thereof
US10533020B2 (en) 2014-09-08 2020-01-14 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1 H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof
AU2015373996B2 (en) * 2014-12-30 2020-10-08 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis B infections
RU2742305C2 (ru) * 2014-12-30 2021-02-04 Новира Терапьютикс, Инк. Производные и способы лечения инфекций гепатита в
US10596184B2 (en) 2015-02-09 2020-03-24 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US10022387B2 (en) 2015-02-09 2018-07-17 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US10479780B2 (en) 2015-06-17 2019-11-19 Chugai Seiyaku Kabushiki Kaisha Aminopyrazole derivatives
WO2016202758A1 (fr) * 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Composés 2-(1h-pyrazol-1-yl)-1h-benzimidazole substitués
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10392383B2 (en) 2015-08-03 2019-08-27 Samumed, Llc 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10472368B2 (en) 2015-11-06 2019-11-12 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
US10544139B2 (en) 2015-11-06 2020-01-28 Samumed, Llc Treatment of osteoarthritis
US10065963B2 (en) 2015-11-06 2018-09-04 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
US10899757B2 (en) 2015-11-06 2021-01-26 Samumed, Llc 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof
US10882860B2 (en) 2015-11-06 2021-01-05 Samumed, Llc Treatment of osteoarthritis
US11773102B2 (en) 2015-11-06 2023-10-03 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
US11667632B2 (en) 2015-11-06 2023-06-06 Biosplice Therapeutics, Inc. 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof
US11560378B2 (en) 2015-11-06 2023-01-24 Biosplice Therapeutics, Inc. Treatment of osteoarthritis
US11091491B2 (en) 2015-11-06 2021-08-17 Incyte Corporation Heterocyclic compounds as PI3K-y inhibitors
US11352340B2 (en) 2016-01-05 2022-06-07 Incyte Corporation Pyridine and pyridimine compounds as PI3K-gamma inhibitors
US11952367B2 (en) 2016-01-05 2024-04-09 Incyte Corporation Pyridine and pyridimine compounds as PI3K-gamma inhibitors
US10787434B2 (en) 2016-03-09 2020-09-29 Ctxt Pty, Ltd Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies
US10519167B2 (en) 2016-03-09 2019-12-31 Ctxt Pty Ltd 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies
US10745380B2 (en) 2016-03-09 2020-08-18 Ctxt Pty Ltd Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies
US11028101B2 (en) 2016-03-09 2021-06-08 Ctxt Pty Ltd 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies
US10421743B2 (en) 2016-03-09 2019-09-24 Ctxt Pty Ltd Tetrahydroisoquinolines as PRMT5 inhibitors
US10550096B2 (en) 2016-03-09 2020-02-04 Ctxt Pty Ltd Tetrahydroisoquinolines as PRMT5 inhibitors
US10961256B2 (en) 2016-03-09 2021-03-30 Ctxt Pty Ltd PRMT5 inhibitors
US10633380B2 (en) 2016-06-01 2020-04-28 Samumed, Llc Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
US10072004B2 (en) 2016-06-01 2018-09-11 Samumed, Llc Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo [4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
US10975088B2 (en) 2016-06-24 2021-04-13 Incyte Corporation Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors
US10479795B2 (en) 2016-06-24 2019-11-19 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
US10196403B2 (en) 2016-07-29 2019-02-05 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
US10927124B2 (en) 2016-07-29 2021-02-23 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
US11077090B2 (en) 2016-07-29 2021-08-03 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
US10806726B2 (en) 2016-10-21 2020-10-20 Samumed, Llc Methods of using indazole-3-carb oxamides and their use as Wnt/B-catenin signaling pathway inhibitors
US11684615B2 (en) 2016-10-21 2023-06-27 Biosplice Therapeutics, Inc. Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors
US11446288B2 (en) 2016-11-07 2022-09-20 Biosplice Therapeutics, Inc. Single-dose, ready-to-use injectable formulations
US10758523B2 (en) 2016-11-07 2020-09-01 Samumed, Llc Single-dose, ready-to-use injectable formulations
US11819499B2 (en) 2016-11-07 2023-11-21 Biosplice Therapeutics, Inc. Single-dose, ready-to-use injectable formulations
US10538511B2 (en) 2016-12-29 2020-01-21 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
US11136309B2 (en) 2016-12-29 2021-10-05 Phasebio Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US10085984B2 (en) 2016-12-29 2018-10-02 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
US11919883B2 (en) 2016-12-29 2024-03-05 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
US11040034B2 (en) 2016-12-29 2021-06-22 Phasebio Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US11129807B2 (en) 2017-02-16 2021-09-28 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
US10780074B2 (en) 2017-08-02 2020-09-22 Sunovion Pharmaceuticals Inc. Compounds and uses thereof
US11491133B2 (en) 2017-08-02 2022-11-08 Sunovion Pharmaceuticals Inc. Heteroaryl-isochroman compounds and uses thereof
US10738057B2 (en) 2017-10-18 2020-08-11 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US11225486B2 (en) 2017-10-18 2022-01-18 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US11926630B2 (en) 2017-10-18 2024-03-12 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US11440921B2 (en) 2018-02-16 2022-09-13 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
US10815249B2 (en) 2018-02-16 2020-10-27 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
CN108546266A (zh) * 2018-07-25 2018-09-18 上海毕得医药科技有限公司 一种1,4,6,7-四氢吡喃[4,3-c]吡唑-3-羧酸的合成方法
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
US11186580B2 (en) 2018-09-05 2021-11-30 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor
US11845753B2 (en) 2018-12-31 2023-12-19 Biomea Fusion, Inc. Inhibitors of menin-mll interaction
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
US11084825B2 (en) 2018-12-31 2021-08-10 Biomea Fusion, Llc Substituted pyridines as irreversible inhibitors of menin-MLL interaction
US11702421B2 (en) 2018-12-31 2023-07-18 Biomea Fusion, Llc Substituted pyridines as irreversible inhibitors of menin-MLL interaction
WO2020150552A3 (fr) * 2019-01-17 2020-08-27 Samumed, Llc Procédés de traitement de troubles du cartilage par inhibition de clk et dyrk
US11136304B2 (en) 2019-03-14 2021-10-05 Sunovion Pharmaceuticals Inc. Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
AU2020405536B2 (en) * 2019-12-20 2023-09-07 Pfizer Inc. Benzimidazole derivatives
RU2803284C1 (ru) * 2019-12-20 2023-09-12 Пфайзер Инк. Производные бензимидазола
US11661419B2 (en) 2019-12-20 2023-05-30 Pfizer Inc. Benzimidazole derivative compounds and uses thereof
CN115087655A (zh) * 2019-12-20 2022-09-20 辉瑞公司 苯并咪唑衍生物
WO2021124155A1 (fr) * 2019-12-20 2021-06-24 Pfizer Inc. Dérivés de benzimidazole
TWI766484B (zh) * 2019-12-20 2022-06-01 美商輝瑞大藥廠 化合物
US11738002B2 (en) 2020-04-14 2023-08-29 Sunovion Pharmaceuticals Inc. Methods of treating neurological and psychiatric disorders
CN112239452A (zh) * 2020-10-14 2021-01-19 武汉尚赛光电科技有限公司 一种电子传输型杂蒽衍生物及其有机电致发光器件
US11958862B2 (en) 2021-01-11 2024-04-16 Sumitomo Pharma America, Inc. Compounds and compositions and uses thereof
CN114478511A (zh) * 2022-02-24 2022-05-13 中国药科大学 苯并恶唑类化合物及其制备方法、药物组合物和应用

Also Published As

Publication number Publication date
CA2465247C (fr) 2010-05-18
IL161576A0 (en) 2004-09-27
JP2005509633A (ja) 2005-04-14
UY27516A1 (es) 2003-04-30
JP5039268B2 (ja) 2012-10-03
EP1441725A1 (fr) 2004-08-04
AU2002334217B2 (en) 2008-07-03
CA2465247A1 (fr) 2003-05-01
MXPA04003954A (es) 2004-11-29
BR0213562A (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
JP5039268B2 (ja) ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
AU2002334217A1 (en) Benzimidazoles and analogues and their use as protein kinases inhibitors
US6897208B2 (en) Benzimidazoles
US10995078B2 (en) Compounds and compositions for inhibition of FASN
JP4377228B2 (ja) ベンゾイミダゾール誘導体、およびｋｄｒキナーゼタンパク質阻害剤としてのその使用
CA2451678C (fr) Azaindoles
KR101288696B1 (ko) 플루오렌 유도체, 상기 유도체를 함유하는 조성물 및이들의 용도
TW200524598A (en) Pharmaceutical compounds
JP2008505167A (ja) 医薬組成物
EP3356345A1 (fr) Dérivés d'hétéroaryle à utiliser en tant qu'inhibiteurs de sépiaptérine réductase
CA2486187A1 (fr) Inhibiteurs de la kinase
US9540349B2 (en) Substituted pyrimidine compounds
EP3774739B1 (fr) Dérivés d'urée cyclique fusionnés utilisés comme antagonistes de crhr2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002801954

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 161576

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003537632

Country of ref document: JP

Ref document number: 2002334217

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/003954

Country of ref document: MX

Ref document number: 2465247

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002801954

Country of ref document: EP